UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

~~June 30,~~March 31, ~~2021~~2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No.

~~001-11596~~1-11596

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation or organization)

58-1954497

(IRS Employer

Identification Number)

8302 Dunwoody Place, Suite 250, Atlanta, GA

(Address of principal executive offices)

30350

(Zip Code)

(770) 587-9898

(Registrant’s telephone number)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $.001 Par Value	PESI	NASDAQ Capital Markets

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated ~~Filer ☐~~ ~~Non-accelerated~~ Filer ☒ Non-accelerated Filer ☐ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the close of the latest practical date.

Class		Outstanding at ~~July 30, 2021~~May 4, 2022
Common Stock, $.001 Par Value		~~12,196,623~~13,256,097 shares

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

INDEX

				Page No.
PART I			FINANCIAL INFORMATION
	Item 1.	Consolidated Financial Statements
		~~Consolidated Balance Sheets - June 30, 2021 and December 31, 2020~~	1
		Consolidated Balance Sheets -March 31, 2022 and December 31, 2021	1
		Consolidated Statements of Operations ~~- Three and Six~~-Three Months Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	3
		Consolidated Statements of Comprehensive ~~Income - Three and Six~~Loss -Three Months Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	4
		Consolidated Statements of Stockholders’ Equity ~~- Six~~-Three Months Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	5
		Consolidated Statements of Cash Flows ~~- Six~~-Three Months Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~	6
		Notes to Consolidated Financial Statements	7
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2321
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3632
	Item 4.	Controls and Procedures	3632

PART II		OTHER INFORMATION
	Item 1.	Legal Proceedings	3733
	Item 1A.	Risk Factors	3733
	Item 6.	Exhibits	3734

PART I - FINANCIAL INFORMATION

Item 1. – Financial Statements

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets

	June 30,			December 31,			March 31,			December 31,
	2021			2020			2022			2021
(Amounts in Thousands, Except for Share and Per Share Amounts)	(Unaudited)			(Audited)			(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	7,312		$	7,924		$	3,925		$	4,440
Accounts receivable, net of allowance for doubtful accounts of $27 and $404, respectively		9,244			9,659
Accounts receivable, net of allowance for doubtful accounts of $26 and $85, respectively								10,322			11,372
Unbilled receivables		7,332			14,453			5,275			8,995
Inventories		701			610			953			680
Prepaid and other assets		2,926			3,967			4,077			4,472
Current assets related to discontinued operations		17			22			27			15
Total current assets		27,532			36,635			24,579			29,974

Property and equipment:
Buildings and land		20,123			20,139			20,642			20,631
Equipment		22,132			22,090			22,531			22,131
Vehicles		454			457			449			443
Leasehold improvements		23			23			23			23
Office furniture and equipment		1,425			1,413			1,316			1,316
Construction-in-progress		2,227			1,569			2,849			2,997
Total property and equipment		46,384			45,691			47,810			47,541
Less accumulated depreciation		(28,574	)		(27,908	)		(29,167	)		(28,932	)
Net property and equipment		17,810			17,783			18,643			18,609

Property and equipment related to discontinued operations		81			81			81			81

Operating lease right-of-use assets		2,317			2,287			2,347			2,460

Intangibles and other long term assets:
Permits		9,118			8,922			9,486			9,476
Other intangible assets - net		885			875			852			894
Finite risk sinking fund (restricted cash)		11,467			11,446			11,482			11,471
Deferred tax assets								4,263			3,527
Other assets		849			890			443			809
Total assets	$	70,059		$	78,919		$	72,176		$	77,301

The accompanying notes are an integral part of these consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets, Continued

	June 30,			December 31,			March 31,			December 31
	2021			2020			2022			2021
(Amounts in Thousands, Except for Share and per Share Amounts)	(Unaudited)			(Audited)			(Unaudited)			(Audited)

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	11,511		$	15,382		$	10,329		$	11,975
Accrued expenses		5,637			6,381			5,537			5,078
Disposal/transportation accrual		1,055			1,220			1,162			1,065
Deferred revenue		3,932			4,614			2,707			5,580
Accrued closure costs - current		74			75			547			578
Current portion of long-term debt		404			3,595			384			393
Current portion of operating lease liabilities		275			273			416			406
Current portion of finance lease liabilities		433			525			354			333
Current liabilities related to discontinued operations		817			898			802			506
Total current liabilities		24,138			32,963			22,238			25,914

Accrued closure costs		6,465			6,290			6,706			6,613
Deferred tax liabilities		474			471
Long-term debt, less current portion		819			3,134			491			600
Long-term operating lease liabilities, less current portion		2,119			2,070			1,921			2,029
Long-term finance lease liabilities, less current portion		555			662			920			884
Other long-term liabilities		626			626
Long-term liabilities related to discontinued operations		256			252			408			677
Total long-term liabilities		11,314			13,505			10,446			10,803

Total liabilities		35,452			46,468			32,684			36,717

Commitments and Contingencies (Note 9)
Commitments and Contingencies (Note 9 )								—			—

Stockholders’ Equity:
Preferred Stock, $.001 par value; 2,000,000 shares authorized, 0 shares issued and outstanding		—			—			—			—
Common Stock, $.001 par value; 30,000,000 shares authorized;12,188,256 and 12,161,539 shares issued, respectively;12,180,614 and 12,153,897 shares outstanding, respectively		12			12
Common Stock, $.001 par value; 30,000,000 shares authorized; 13,242,072 and 13,222,552 shares issued, respectively; 13,234,430 and 13,214,910 shares outstanding, respectively								13			13
Additional paid-in capital		109,206			108,931			114,532			114,307
Accumulated deficit		(72,555	)		(74,455	)		(74,963	)		(73,620	)
Accumulated other comprehensive loss		(167	)		(207	)		(2	)		(28	)
Less Common Stock in treasury, at cost; 7,642 shares		(88	)		(88	)		(88	)		(88	)
Total Perma-Fix Environmental Services, Inc. stockholders’ equity		36,408			34,193
Non-controlling interest		(1,801	)		(1,742	)
Total stockholders’ equity		34,607			32,451			39,492			40,584

Total liabilities and stockholders’ equity	$	70,059		$	78,919		$	72,176		$	77,301

The accompanying notes are an integral part of these consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Operations

(Unaudited)


	Three Months Ended						Six Months Ended
(Amounts in Thousands, Except for Per Share Amounts)													2022			2021
	June 30,						June 30,						Three Months Ended March 31,
(Amounts in Thousands, Except for Per Share Amounts)	2021			2020			2021			2020			2022			2021

Net revenues	$	16,145		$	22,047		$	39,278		$	46,907
Revenues													$	15,915		$	23,133
Cost of goods sold		15,179			18,737			35,956			38,957			14,279			20,777
Gross profit		966			3,310			3,322			7,950			1,636			2,356

Selling, general and administrative expenses		2,997			2,700			6,202			5,627			3,422			3,205
Research and development		144			209			295			441			96			150
(Gain) loss on disposal of property and equipment		—			(4)			—			27
(Loss) income from operations		(2,175	)		405			(3,175	)		1,855
Loss on disposal of property and equipment														1			—
Loss from operations														(1,883	)		(999	)

Other income (expense):
Interest income		2			28			21			84			11			18
Interest expense		(65	)		(99	)		(132	)		(219	)		(35	)		(67	)
Interest expense-financing fees		(9	)		(60	)		(17	)		(129	)		(13	)		(8	)
Other		—			4			1			9		(2	)		1
Gain (loss) on extinguishment of debt		5,381			(27	)		5,381			(27	)
Income from continuing operations before taxes		3,134			251			2,079			1,573
Income tax expense (benefit)		13			(9	)		(4	)		5
Income from continuing operations, net of taxes		3,121			260			2,083			1,568
Loss from continuing operations before taxes														(1,922	)		(1,055	)
Income tax benefit														(673	)		(17	)
Loss from continuing operations, net of taxes														(1,249	)		(1,038	)

Loss from discontinued operations (net of taxes of $0)		(127	)		(85	)		(242	)		(199	)
Net income		2,994			175			1,841			1,369
Loss from discontinued operations (net of taxes) (Note 10)														(94	)		(115	)
Net loss														(1,343	)		(1,153	)

Net loss attributable to non-controlling interest		(29	)		(29	)		(59	)		(55	)		—			(30	)

Net income attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	3,023		$	204		$	1,900		$	1,424
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders													$	(1,343	)	$	(1,123	)

Net income (loss) per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic:
Net loss per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic and diluted:
Continuing operations	$	.26		$	.02		$	.18		$	.13		$	(.09	)	$	(.08	)
Discontinued operations		(.01	)		—			(.02	)		(.01	)		(.01	)		(.01	)
Net income per common share	$	.25		$	.02		$	.16		$	.12
Net loss per common share													$	(.10	)	$	(.09	)

Net income (loss) per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - diluted:

Continuing operations	$	.25		$	.02		$	.17		$	.13
Discontinued operations		(.01	)		—			(.02	)		(.01)
Net income per common share	$	.24		$	.02		$	.15		$	.12

Number of common shares used in computing net income per share:
Number of common shares used in computing net loss per share:
Basic		12,180			12,135			12,173			12,129			13,234			12,165
Diluted		12,440			12,286			12,420			12,320			13,234			12,165

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Comprehensive ~~Income~~Loss

(Unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
(Amounts in Thousands) 2021 2020 2021 2020

Net income $ 2,994 $ 175 $ 1,841 $ 1,369
Other comprehensive income (loss):
Foreign currency translation gain (loss) 20 28 40 (51 )

Comprehensive income 3,014 203 1,881 1,318
Comprehensive loss attributable to non-controlling interest (29 ) (29 ) (59 ) (55 )
Comprehensive income attributable to Perma-Fix Environmental Services, Inc. stockholders $ 3,043 $ 232 $ 1,940 $ 1,373

(Amounts in Thousands)	2022			2021
	Three Months Ended March 31,
(Amounts in Thousands)	2022			2021

Net loss	$	(1,343	)	$	(1,153	)
Other comprehensive income:
Foreign currency translation gain		26			20
Total other comprehensive income		26			20

Comprehensive loss		(1,317	)		(1,133	)
Comprehensive loss attributable to non-controlling interest		—			(30	)
Comprehensive loss attributable to Perma-Fix Environmental Services, Inc. stockholders	$	(1,317	)	$	(1,103	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC

Consolidated Statement of Stockholders’ Equity

(Unaudited)

(Amounts in thousands, except for share amounts)

																						Shares		Amount		Capital		Treasury			Loss			Subsidiary			Deficit			Equity
	Common Stock				Additional Paid-In		Common Stock Held In			Accumulated Other Comprehensive			Non-controlling Interest in			Accumulated			Total Stockholders’			Common Stock				Additional Paid-In		Common Stock Held In			Accumulated Other Comprehensive			Non-controlling Interest in			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Treasury			Loss			Subsidiary			Deficit			Equity			Shares		Amount		Capital		Treasury			Loss			Subsidiary			Deficit			Equity

Balance at December 31, 2021																							13,222,552	$	13	$	114,307	$	(88	)	$	(28	)	$	—		$	(73,620	)	$	40,584
Net loss																							—		—		—		—			—			—			(1,343	)		(1,343	)
Foreign currency translation																							—		—		—		—			26			—			—			26
Issuance of Common Stock for services																							19,520		—		123		—			—			—			—			123
Stock-Based Compensation																							—		—		102		—			—			—			—			102
Balance at March 31, 2022																							13,242,072	$	13	$	114,532	$	(88	)	$	(2	)	$	—		$	(74,963	)	$	39,492

Balance at December 31, 2020		12,161,539	$	12	$	108,931	$	(88	)	$	(207	)	$	(1,742	)	$	(74,455	)	$	32,451			12,161,539	$	12	$	108,931	$	(88	)	$	(207	)	$	(1,742	)	$	(74,455	)	$	32,451
Net loss		—		—		—		—			—			(30	)		(1,123	)		(1,153	)		—		—		—		—			—			(30	)		(1,123	)		(1,153	)
Net Income (loss)		—		—		—		—			—			(30	)		(1,123	)		(1,153	)
Foreign currency translation		—		—		—		—			20			—			—			20			—		—		—		—			20			—			—			20
Issuance of Common Stock for services		11,837		—		79		—			—			—			—			79			11,837		—		79		—			—			—			—			79
Stock-Based Compensation		—		—		45		—			—			—			—			45			—		—		45		—			—			—			—			45
Balance at March 31, 2021		12,173,376	$	12	$	109,055	$	(88	)	$	(187	)	$	(1,772	)	$	(75,578	)	$	31,442			12,173,376	$	12	$	109,055	$	(88	)	$	(187	)	$	(1,772	)	$	(75,578	)	$	31,442
Net Income (loss)		—		—		—		—			—			(29	)		3,023			2,994
Foreign currency translation		—		—		—		—			20			—			—			20
Issuance of Common Stock upon exercise of options		290		—		—		—			—			—			—			—
Issuance of Common Stock for services		14,590		—		109		—			—			—			—			109
Stock-Based Compensation		—		—		42		—			—			—			—			42
Balance at June 30, 2021		12,188,256	$	12	$	109,206	$	(88	)	$	(167	)	$	(1,801	)	$	(72,555	)	$	34,607

Balance at December 31, 2019		12,123,520	$	12	$	108,457	$	(88	)	$	(211	)	$	(1,619	)	$	(77,315	)	$	29,236
Net Income (loss)		—		—		—		—			—			(26	)		1,220			1,194
Foreign currency translation		—		—		—		—			(79	)		—			—			(79	)
Issuance of Common Stock upon exercise of options		3,643		—		6		—			—			—			—			6
Issuance of Common Stock for services		5,128		—		48		—			—			—			—			48
Stock-Based Compensation		—		—		44		—			—			—			—			44
Balance at March 31, 2020		12,132,291	$	12	$	108,555	$	(88	)	$	(290	)	$	(1,645	)	$	(76,095	)	$	30,449
Net Income (loss)		—		—		—		—			—			(29	)		204			175
Foreign currency translation		—		—		—		—			28			—			—			28
Issuance of Common Stock upon exercise of options		241		—		—		—			—			—			—			—
Issuance of Common Stock for services		10,239		—		56		—			—			—			—			56
Stock-Based Compensation		—		—		48		—			—			—			—			48
Balance at June 30, 2020		12,142,771	$	12	$	108,659	$	(88	)	$	(262	)	$	(1,674	)	$	(75,891	)	$	30,756

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Cash Flows

(Unaudited)


(Amounts in Thousands)							2022			2021
	Six Months Ended						Three Months Ended
	June 30,						March 31,
(Amounts in Thousands)	2021			2020			2022			2021
Cash flows from operating activities:
Net income	$	1,841		$	1,369
Less: loss from discontinued operations, net of taxes of $0		(242	)		(199	)
Net loss							$	(1,343	)	$	(1,153	)
Less: loss from discontinued operations, net of taxes (Note 10)								(94	)		(115	)

Income from continuing operations, net of taxes		2,083			1,568
Adjustments to reconcile income from continuing operations to cash provided by operating activities:
Loss from continuing operations, net of taxes								(1,249	)		(1,038	)
Adjustments to reconcile loss from continuing operations to cash provided by (used in) operating activities :
Depreciation and amortization		799			711			456			400
Interest on finance lease with purchase option		4			4			—			2
(Gain) loss on extinguishment of debt		(5,381	)		27
Amortization of debt discount/debt issuance costs		17			129
Deferred tax expense		3			5
Amortization of debt issuance costs								13			8
Deferred tax benefit								(673	)		—
Recovery of bad debt reserves		(17	)		(107	)		(55	)		(17	)
Loss on disposal of property and equipment		—			27
Loss on disposal of plant, property, and equipment								1			—
Issuance of common stock for services		188			104			123			79
Stock-based compensation		87			92			102			45
Changes in operating assets and liabilities of continuing operations
Changes in operating assets and liabilities of continuing operations:
Accounts receivable		432			2,479			1,105			(10,445	)
Unbilled receivables		7,121			(3,085	)		3,720			5,224
Prepaid expenses, inventories and other assets		1,076			714			1,097			557
Accounts payable, accrued expenses and unearned revenue		(5,609	)		289			(4,492	)		(1,270	)
Cash provided by continuing operations		803			2,957
Cash provided by (used in) continuing operations								148			(6,455	)
Cash used in discontinued operations		(315	)		(259	)		(142	)		(149	)
Cash provided by operating activities		488			2,698
Cash provided by (used in) operating activities								6			(6,604	)

Cash flows from investing activities:
Purchases of property and equipment		(650	)		(1,366	)		(345	)		(361	)
Proceeds from sale of property and equipment		1			4
Proceeds from sale of plant, property, and equipment								24			1
Cash used in investing activities of continuing operations		(649	)		(1,362	)		(321	)		(360	)
Cash provided by investing activities of dicontinued operations		—			13
Cash used in investing activities		(649	)		(1,349	)

Cash flows from financing activities:
Repayments of revolving credit borrowings		(41,834	)		(47,058	)		(17,494	)		(14,780	)
Borrowing on revolving credit		41,834			46,737			17,494			14,780
Proceeds from issuance of long-term debt		—			5,666
Principal repayments of finance lease liabilities		(205	)		(229	)		(58	)		(114	)
Principal repayments of long term debt		(219	)		(1,045	)		(110	)		(109	)
Payment of debt issuance costs		(15	)		(85	)		(21	)		—
Proceeds from issuance of common stock upon exercise of options		—			6
Cash (used in) provided by financing activities of continuing operations		(439	)		3,992
Cash used in financing activities								(189	)		(223	)

Effect of exchange rate changes on cash		9			(18	)		—			(6	)

(Decrease) increase in cash and finite risk sinking fund (restricted cash)		(591	)		5,323			(504	)		(7,193	)
Cash and finite risk sinking fund (restricted cash) at beginning of period		19,370			11,697			15,911			19,370
Cash and finite risk sinking fund (restricted cash) at end of period	$	18,779		$	17,020		$	15,407		$	12,177

Supplemental disclosure:
Interest paid	$	106		$	207		$	34		$	54
Income taxes paid		15			30			6			—
Non-cash financing activities:
Non-cash investing and financing activities:
Equipment purchase subject to finance lease		—			132			114			—
Equipment purchase subject to finance		29			—
Equipment purchase subject to financing								—			29

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Notes to Consolidated Financial Statements

~~June 30, 2021~~

March 31, 2022

(Unaudited)

Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

1. ~~Basis of Presentation~~

1.	Basis of Presentation

The consolidated financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“the Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the consolidated financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 are not necessarily indicative of results to be expected for the fiscal year ending December 31, ~~2021.~~2022.

The Company suggests that these consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

The consolidated financial statements include ~~our~~the accounts ~~those~~ of our wholly-owned subsidiaries and ~~our majority-owned Polish subsidiary, Perma-Fix Medical. Additionally, the Company’s financial statements include~~ the account of a variable interest entity (“VIE”), Perma-Fix ERRG for which we are the primary beneficiary (See “Note 13 - VIE” for a discussion of this VIE). The consolidated financial statements for 2021 also included the accounts of the Company’s majority-owned Polish subsidiary, Perma-Fix Medical S.A (“PFM Poland”) and PFM Poland’s wholly-owned subsidiary, Perma-Fix Medical Corporation (“PFMC”), which comprised of the Company’s Medical Segment. As previously discussed, the Company made the strategic decision to cease all research and development (“R&D”) activities under the Medical Segment and sold 100% of its interest in PFM Poland in December 2021. As a condition precent to the sale of PFM Poland, the Company acquired PFMC after its conversion to a Delaware limited liability company. As a result of the sale of PFM Poland, the Company deconsolidated PFM Poland from its consolidated financial statements in December 2021. The Company’s Medical Segment had not generated any revenue.

2. ~~Summary~~Information for the Medical Segment is presented for the quarter ending March 31, 2021. The Medical Segment was disposed of ~~Significant Accounting Policies~~as of December 31, 2021 and is not relevant for the quarter ending March 31, 2022. Prior period segment information is not required to be restated for the disposal of the segment.

2.	Summary of Significant Accounting Policies

Our accounting policies are as set forth in the notes to the December 31, ~~2020~~2021 consolidated financial statements referred to above.

Recently Adopted Accounting Standards

In ~~December 2019,~~May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. ~~2019-12, “Income Taxes~~2021-04, “Earnings Per Share (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740206), Debt-Modifications and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU No. 2019-12 by the Company effective January 1, 2021 did not have a material impact on the Company’s financial statements.

~~In January 2020, the FASB issued ASU 2020-01, “Investments - Equity Securities~~Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic ~~321), Investments - Equity Method and Joint Ventures (Topic 323)~~718), and Derivatives and ~~Hedging (Topic 815), clarifying~~Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the ~~Interactions between Topic 321, Topic 323, and Topic 815.~~FASB Emerging Issues Task Force).” ~~This guidance~~ASU 2021-04 addresses issuer’s accounting for ~~the transition into and out~~certain modifications or exchanges of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities.freestanding equity-classified written call options. This ~~standard~~ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The adoption of ASU No. 2020-01 by the Company effective January 1, 2021 did not have a material impact on the Company’s financial statements.

In October 2020, the FASB issued ASU No 2020-10, “Codification Improvements.” ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for publicall entities, for fiscal years beginning after December 15, ~~2020, with early~~2021, including interim periods within those fiscal years. Early adoption is permitted. The adoption of this ASU ~~No. 2020-01~~ by the Company effective January 1, ~~2021~~2022 did not have a material impact on ~~the Company’s~~its financial ~~statements or disclosures.~~statements.

Recently Issued Accounting Standards – Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, “Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments,” and various subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables and loans. Entities are required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, FASB issued ASU 2019-10, “Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies (“SRC”) as defined by the Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. These ASUs are effective January 1, 2023 for the Company as ~~a smaller reporting company (“SRC”).~~an SRC. Under new guidance issued by the Commission in March 2020, the Company ~~will continue~~continues to qualify as a smaller reporting company but ~~will also be~~became an accelerated filer ~~for~~starting with its 2021 Form 10-K and all ~~filings with the Commission after January 1, 2022.~~subsequent filings. The Company is currently evaluating the impact of these ASU on its consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope,” which clarified the scope and application of the original guidance. The Company plans to adopt both ASUs when LIBOR is discontinued. The Company is currently evaluating the impact of the new ASUs on its condensed consolidated financial statements. As of the date of this report, the Company has determined that only its obligations under the credit facility as described in “Note 8 – Long Term Debt would be impacted by these ASUs. The Company’s obligations under its credit facility permit for payment of annual rate of interests on its obligations using prime rate or LIBOR.

In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models and removing certain settlement condition qualifiers for the derivatives scope exception for contracts in an entity’s own equity, and simplifies the related diluted net income per share calculation for both Subtopics. ASU 2020-06 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, for the Company as ~~a smaller reporting company.~~an SRC. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and disclosures.

In May 2021, the FASB issued ASU No. 2021-04, “Earnings Per Share (Topic 206), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).” ASU 2021-04 addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This ASU is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

3. ~~Revenue~~

3.	Revenue

Disaggregation of Revenue

In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of our services and provides meaningful disaggregation of each business segment’s results of operations. The nature of the Company’s performance obligations within our Treatment and Services Segments ~~result~~results in the recognition of our revenue primarily over time. The following tables present further disaggregation of our revenues by different categories for our Services and Treatment Segments:

Schedule ofOf Disaggregation ofOf Revenue

Revenue by Contract Type
(In thousands) Three Months Ended Three Months Ended
June 30, 2021 June 30, 2020
Treatment Services Total Treatment Services Total
Fixed price $ 7,706 $ 1,482 $ 9,188 $ 7,840 $ 2,329 $ 10,169
Time and materials — 6,957 6,957 — 11,878 11,878
Total $ 7,706 $ 8,439 $ 16,145 $ 7,840 $ 14,207 $ 22,047

Revenue by Contract Type
(In thousands)	Three Months Ended						Three Months Ended
	March 31, 2022						March 31, 2021
	Treatment		Services		Total		Treatment		Services		Total
Fixed price	$	7,479	$	5,761	$	13,240	$	7,495	$	2,581	$	10,076
Time and materials		—		2,675		2,675		—		13,057		13,057
Total	$	7,479	$	8,436	$	15,915	$	7,495	$	15,638	$	23,133

Revenue by Contract Type
(In thousands) Six Months Ended Six Months Ended
June 30, 2021 June 30, 2020
Treatment Services Total Treatment Services Total
Fixed price $ 15,201 $ 4,063 $ 19,264 $ 17,403 $ 3,721 $ 21,124
Time and materials — 20,014 20,014 — 25,783 25,783
Total $ 15,201 $ 24,077 $ 39,278 $ 17,403 $ 29,504 $ 46,907

Revenue by generator
(In thousands) Three Months Ended Three Months Ended
June 30, 2021 June 30, 2020
Treatment Services Total Treatment Services Total
Domestic government $ 5,639 $ 6,764 $ 12,403 $ 6,055 $ 12,791 $ 18,846
Domestic commercial 2,060 391 2,451 1,785 431 2,216
Foreign government 7 1,261 1,268 — 965 965
Foreign commercial — 23 23 — 20 20
Total $ 7,706 $ 8,439 $ 16,145 $ 7,840 $ 14,207 $ 22,047

Revenue by generator
(In thousands) Six Months Ended Six Months Ended
June 30, 2021 June 30, 2020
Treatment Services Total Treatment Services Total
Domestic government $ 10,237 $ 19,425 $ 29,662 $ 13,745 $ 26,589 $ 40,334
Domestic commercial 4,328 981 5,309 3,658 893 4,551
Foreign government 541 3,625 4,166 — 1,979 1,979
Foreign commercial 95 46 141 — 43 43
Total $ 15,201 $ 24,077 $ 39,278 $ 17,403 $ 29,504 $ 46,907

~~Contract Balances~~

Revenue by generator
(In thousands)	Three Months Ended						Three Months Ended
	March 31, 2022						March 31, 2021
	Treatment		Services		Total		Treatment		Services		Total
Domestic government	$	5,815	$	8,245	$	14,060	$	4,598	$	12,661	$	17,259
Domestic commercial		1,436		162		1,598		2,265		590		2,855
Foreign government		92		6		98		534		2,364		2,898
Foreign commercial		136		23		159		98		23		121
Total	$	7,479	$	8,436	$	15,915	$	7,495	$	15,638	$	23,133

~~The timing of revenue recognition, billings, and cash collections results in accounts receivable and unbilled receivables (contract assets).~~ Contract Liabilities

The Company’s contract liabilities consist of deferred revenues which ~~represents~~represent advance payment from customers in advance of the completion of our performance obligation.

The following table represents changes in our contract ~~assets and contract~~ liabilities balances:

Schedule ofOf Contract ~~Assets and~~ Liabilities

	June 30,		December 31,		Year-to-date			Year-to-date							Year-to-date			Year-to-date
(In thousands)	2021		2020		Change ($)			Change (%)			March 31, 2022		December 31, 2021		Change ($)			Change (%)
Contract assets
Account receivables, net of allowance	$	9,244	$	9,659	$	(415	)		(4.3	)%
Unbilled receivables - current		7,332		14,453		(7,121	)		(49.3	)%

Contract liabilities
Deferred revenue	$	3,932	$	4,614	$	(682	)		(14.8	)%	$	2,707	$	5,580	$	(2,873	)		(51.5	)%

The decrease was primarily due to revenue recognized in connection with a Services Segment contract. The decrease was also attributed to more processing of Treatment Segment’s backlog due to continued delays in waste receipts from certain customers from the impact of COVID-19.

During the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, the Company recognized revenue of $~~1,763,000~~3,521,000 and $~~6,074,000~~, respectively, related to untreated waste that was in the Company’s control as of the beginning of each respective year. During the three and six months ended June 30, 2020, the Company recognized revenue of $~~2,516,000~~ ~~and $6,539,000~~4,311,000, respectively, related to untreated waste that was in the Company’s control as of the beginning of each respective year. Revenue recognized in each period related to performance obligations satisfied within the respective period.

Remaining Performance Obligations

The Company applies the practical expedient in ~~ASC~~paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.

Within our Services Segment, there are service contracts which provide that the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of our performance completed to date. For those contracts, the Company has utilized the practical expedient in ASC 606-10-55-18, which allows the Company to recognize revenue in the amount for which we have the right to invoice; accordingly, the Company does not disclose the value of remaining performance obligations for those contracts.

4. ~~Leases~~The Company’s contracts and subcontracts relating to activities at governmental sites generally allow for termination for convenience at any time at the government’s option without payment of a substantial penalty. The Company does not disclose remaining performance obligations on these contracts.

4.	Leases

At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on facts and circumstances present in that arrangement. Lease classifications, recognition, and measurement are then determined at the lease commencement date.

The Company’s operating lease right-of-use (“ROU”) assets and operating lease liabilities represent primarily leases for office and warehouse spaces used to conduct our business. Finance leases consist primarily of processing and transport equipment used by our facilities’ ~~operations and also include a building with land for our waste treatment~~ operations.

The components of lease cost for the Company’s leases ~~for the three and six months ended June 30, 2021 and 2020~~ were as follows (in thousands):

Schedule ofOf Components ofOf Lease Cost

									2022		2021
	Three Months Ended				Six Months Ended				Three Months Ended
	June 30,				June 30,				March 31,
	2021		2020		2021		2020		2022		2021

Operating Leases:
Operating Lease:
Lease cost	$	115	$	114	$	226	$	228	$	157	$	111

Finance Leases:
Amortization of ROU assets		58		26		117		52		47		59
Interest on lease liability		18		29		37		50		11		19
Finance Leases		76		55		154		102
Finance leases										58		78

Short-term lease rent expense		3		1		6		4		3		3

Total lease cost		194		170		386		334	$	218	$	192

The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at ~~June 30,~~March 31, 2022 were:

Schedule Of Weighted Average Lease

	Operating Leases			Finance Leases
Weighted average remaining lease terms (years)		6.7			4.0

Weighted average discount rate		7.6	%		6.1	%

The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2021 were:

~~Schedule of Weighted Average Lease~~

	Operating Leases			Finance Leases			Operating Leases			Finance Leases
Weighted average remaining lease terms (years)		7.6			3.2			7.8			3.4

Weighted average discount rate		7.7	%		6.2	%		7.8	%		6.8	%

The following table reconciles the undiscounted cash flows for the operating and finance leases at ~~June 30, 2021~~March 31, 2022 to the operating and finance lease liabilities recorded on the balance sheet (in thousands):

Schedule ofOf Operating ~~and~~And Finance Lease Liability Maturity

Operating Leases Finance Leases
2021 (Remaining) $ 211 $ 353
2022 478 271
2023 486 150
2024 419 146
2025 327 146
2025 and thereafter 1,260 18
Total undiscounted lease payments 3,181 1,084
Less: Imputed interest (787 ) (96 )
Present value of lease payments $ 2,394 $ 988

Current portion of operating lease obligations $ 275 $ —
Long-term operating lease obligations, less current portion $ 2,119 $ —
Current portion of finance lease obligations $ — $ 433
Long-term finance lease obligations, less current portion $ — $ 555

	Operating Leases			Finance Leases
2022 (Remaining)	$	433		$	315
2023		560			327
2024		419			323
2025		328			300
2026		304			171
2027 and thereafter		955			20
Total undiscounted lease payments		2,999			1,456
Less: Imputed interest		(662	)		(182	)
Present value of lease payments	$	2,337		$	1,274

Current portion of operating lease obligations	$	416		$	—
Long-term operating lease obligations, less current portion	$	1,921		$	—
Current portion of finance lease obligations	$	—		$	354
Long-term finance lease obligations, less current portion	$	—		$	920

Supplemental cash flow and other information related to our leases were as follows ~~for the three and six months ended June 30, 2021 and 2020~~ (in thousands):

Schedule ofOf Supplemental Cash Flow ~~and~~And Other Information Related toTo Leases

									2022		2021
	Three Months Ended				Six Months Ended				Three Months Ended
	June 30,				June 30,				March 31,
	2021		2020		2021		2020		2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow used in operating leases	$	103	$	110	$	204	$	220
Operating cash flow used in finance leases	$	18	$	29	$	37	$	50
Financing cash flow used in finance leases	$	91	$	128	$	205	$	229
Operating cash flow from operating leases									$	143	$	101
Operating cash flow from finance leases									$	11	$	19
Financing cash flow from finance leases									$	58	$	114

ROU assets obtained in exchange for lease obligations for:
Finance liabilities	$	—	$	41	$	—	$	123	$	147	$	—
Operating liabilities	$	166		—		166		—	$	—	$	—

5. ~~Intangible Assets~~

5.	Intangible Assets

The following table summarizes information relating to the Company’s definite-lived intangible assets:

Schedule ~~of Finite-Lived~~Of Definite Lived Intangible Assets

June 30, 2021 December 31, 2020

Weighted Average
Amortization
Gross Net Gross Net
Period Carrying Accumulated Carrying Carrying Accumulated Carrying
(Years) Amount Amortization Amount Amount Amortization Amount
Intangibles (amount in thousands)
Patent 12.5 $ 746 $ (343 ) $ 403 $ 742 $ (334 ) $ 408
Software 3 524 (413 ) 111 418 (411 ) 7
Customer relationships 10 3,370 (2,999 ) 371 3,370 (2,910 ) 460
Total $ 4,640 $ (3,755 ) $ 885 $ 4,530 $ (3,655 ) $ 875

			March 31, 2022							December 31, 2021
	Weighted Average Amortization		Gross					Net		Gross					Net
	Period		Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
	(Years)		Amount		Amortization			Amount		Amount		Amortization			Amount
Other Intangibles (amount in thousands)
Patent		8.3	$	787	$	(354	)	$	433	$	787	$	(351	)	$	436
Software		3		606		(428	)		178		592		(415	)		177
Customer relationships		10		3,370		(3,129	)		241		3,370		(3,089	)		281
Total			$	4,763	$	(3,911	)	$	852	$	4,749	$	(3,855	)	$	894

The intangible assets noted above are amortized on a straight-line basis over their useful lives with the exception of customer relationships which are being amortized using an accelerated method.

The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets:

Schedule ~~of Finite-Lived~~Of Finite Lived Intangible Assets, Future Amortization Expense

			Amount
Year	(In thousands)		(In thousands)

2021(remaining)	$	123
2022		198
2022 (Remaining)			$	164
2023		158		178
2024		37		46
2025		14		11
2026				11

Amortization expenses relating to the definite-lived intangible assets as discussed above were $~~50,000~~56,000 and $~~100,000~~50,000 for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~respectively, and $55,000~~ ~~and $109,000~~ ~~for the three and six months ended June 30, 2020,~~ respectively.

6. ~~Capital Stock, Stock Plans and Stock Based Compensation~~

6.	Capital Stock, Stock Plans, Warrants and Stock Based Compensation

The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants.

~~On May 4, 2021,~~ No stock options were granted in the ~~Company granted~~ ~~6,000~~ ~~NQSOs from the Company’s 2003 Outside Directors Stock Plan (“2003 Plan”) to a new director elected by the Company’s Board~~first quarter of ~~Directors (“Board”) to fill a vacancy on the Board. The options granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the options was $7.50~~ ~~per share, which was equal to the Company’s closing stock price per share the day preceding the grant date, pursuant to the 2003 Plan.~~2022.

The Company granted a NQSO to Robert Ferguson on July 27, 2017 from the Company’s 2017 Stock Option Plan (“2017 Plan”) for the purchase of up to 100,000 shares of the Company’s Common Stock (“Ferguson Stock Option”) in connection with his work as a consultant to the Company’s Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility at an exercise price of $3.65 per share, which was the fair market value of the Company’s Common Stock on the date of grant. The term of the Ferguson Stock Option is seven years from the grant date. The vesting of the Ferguson Stock Option is subject to the achievement of three separate milestones by certain dates. The ~~10,000~~ ~~options~~first milestone was met and the shares under the first milestone were ~~exercised by~~issued to Robert Ferguson in May 2018. The Company had previously entered into amendments whereby the vesting ~~date~~dates for the second and third milestones for the purchase of up to 30,000 and 60,000 shares of the Company’s Common Stock ~~was previously~~were extended to December 31, 2021 and December 31, 2022, respectively. On January 20, 2022, the Company’s Compensation and Stock Option Committee (“Compensation Committee”) and the Board of Directors (“Board”) further amended the vesting dates of the second and third milestones to December 31, 2022 and December 31, 2023, respectively. This amendment was approved by the Compensation Committee and the Board to take effect December 31, 2021. The Company has not recognized compensation costs (fair value of approximately $~~262,000~~289,000 at ~~June 30, 2021)~~March 31, 2022) for the remaining 90,000 Ferguson Stock Option under the remaining two milestones since achievement of the performance obligation under each of the two remaining milestones is uncertain at ~~June 30, 2021.~~March 31, 2022. All other terms of the Ferguson Stock Option remain unchanged.

The Company estimates fair value of stock options using the Black-Scholes valuation model. Assumptions used to estimate the fair value of stock options granted include the exercise price of the award, the expected term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the expected annual dividend yield. The fair value of the options granted on May 4, 2021 as discussed above and the related assumptions used in the Black-Scholes option model used to value the options granted were as follows:

~~Schedule of Stock Options Valuation Assumptions~~

Outside Director Stock Options Granted
May 4, 2021
Weighted-average fair value per option $ 4.97
Risk -free interest rate ⁽¹⁾ 1.61 %
Expected volatility of stock ⁽²⁾ 55.91 %
Dividend yield NaN
Expected option life ⁽³⁾ 10.0 years

⁽¹⁾	~~The risk-free interest rate is based on the U.S. Treasury yield in effect at the grant date over the expected term of the option.~~

⁽²⁾	~~The expected volatility is based on historical volatility from our traded Common Stock over the expected term of the option.~~

⁽³⁾	~~The expected option life is based on historical exercises and post-vesting data.~~

The following table summarizes stock-based compensation recognized for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ for our employee and director stock options.

Schedule of Share-based Compensation, Allocation of Recognized Period Costs

	2021		2020		2021		2020			2022	2021
	Three Months Ended				Six Months Ended				Three Months Ended
Stock Options	June 30,				June 30,				March 31,
	2021		2020		2021		2020		2022			2021
Employee Stock Options	$	33,000	$	33,000	$	66,000	$	65,000	$	86,000		$	33,000
Director Stock Options		9,000		15,000		21,000		27,000		16,000			12,000
Total	$	42,000	$	48,000	$	87,000	$	92,000	$	102,000		$	45,000
Stock-based compensation	$	42,000	$	48,000	$	87,000	$	92,000

At ~~June 30, 2021,~~March 31, 2022, the Company has approximately $~~215,000~~1,287,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately ~~1.6~~4.1 years.

The summary of the Company’s total Stock Option Plans as of ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan, the 2017 ~~Plans~~Plan and the 2003 ~~Plan:~~Outside Directors Stock Plan (“2003 Plan”):

Schedule of Stock Options Roll Forward

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽⁴⁾		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽³⁾
Options outstanding January 1, 2021		658,400		$	3.87
Options outstanding January 1, 2022											1,019,400	$	4.91				—
Granted		6,000		$	7.50						—	$	—
Exercised		(500	)	$	3.15			$	2,175		—	$	—			$	—
Forfeited/expired		(1,500	)	$	3.15						—	$	—
Options outstanding end of period ⁽¹⁾		662,400		$	3.90		3.1	$	2,153,595		1,019,400	$	4.91		3.8	$	1,150,167
Options exercisable at June 30, 2021⁽²⁾		391,900		$	4.08		3.1	$	1,202,495
Options exercisable at March 31, 2022⁽¹⁾											455,900	$	3.92		2.5	$	779,362

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽⁴⁾		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽³⁾
Options outstanding January 1, 2020		681,300		$	3.84
Options outstanding January 1, 2021											658,400	$	3.87				—
Granted		6,000		$	7.00				16,060		—		—
Exercised		(12,500	)	$	3.47						—		—			$	—
Forfeited/expired		(20,000	)	$	3.45						—		—
Options outstanding end of period ⁽³⁾⁽²⁾		654,800		$	3.88		3.7	$	1,685,031		658,400	$	3.87		3.2	$	2,279,267
Options exercisable as of June 30, 2020⁽³⁾		306,800		$	4.20		3.6	$	711,306
Options exercisable at March 31, 2021⁽²⁾											392,400	$	4.08		3.4	$	1,274,287

⁽¹⁾	Options with exercise prices ranging from $2.79 to $7.50

⁽²⁾	Options with exercise prices ranging from $2.79 to $7.29

⁽³⁾	~~Options with exercise prices ranging from $2.79~~ ~~to $8.40~~

⁽⁴⁾	The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise ~~price.~~price of the option.

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company issued a total of ~~26,427~~19,520 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board. The Company ~~has~~ recorded approximately $~~221~~120,000~~,000~~ in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors. See “Note 15 – Subsequent Events - 2003 Plan” for a discussion of an amendment to the 2003 Plan as approved by the Company’s Stockholder at the Company’s 2021 Annual Meeting of Stockholders held on July 20, 2021.

~~During~~In connection with a $2,500,000 loan that the ~~six months ended June 30, 2021,~~Company entered into with Mr. Robert Ferguson (the “Ferguson Loan”) on April 1, 2019, the Company issued ~~290~~ ~~shares of its Common Stock from~~ a ~~cashless exercise of an option~~warrant to Mr. Ferguson for the purchase of up to ~~500~~60,000 shares of ~~the Company’s~~our Common Stock at an exercise price of $~~3.15~~3.51 per share.The warrant expires on April 1, 2024 and remains outstanding at March 31, 2022. The Ferguson Loan was paid-in-full in December 2020.

7. ~~Income Per Share~~

7.	Loss Per Share

Basic ~~income~~loss per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted ~~income~~loss per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive loss earnings per ~~share.~~shares. The following table reconciles the ~~income~~loss and average share amounts used to compute both basic and diluted ~~income~~loss per share:

Schedule of ~~Earnings~~Earning Per Share ~~Basic and Diluted~~

Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited) (Unaudited)
(Amounts in Thousands, Except for Per Share Amounts) 2021 2020 2021 2020
Net income (loss) attributable to Perma-Fix Environmental Services,Inc., common stockholders:
Income from continuing operations, net of taxes $ 3,121 $ 260 $ 2,083 $ 1,568
Net loss attributable to non-controlling interest (29 ) (29 ) (59 ) (55 )
Income from continuing operations attributable to
Perma-Fix Environmental Services, Inc. common stockholders
3,150 289 2,142 1,623
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders (127 ) (85 ) (242 ) (199 )
Net income attributable to Perma-Fix Environmental Services, Inc. common stockholders $ 3,023 $ 204 $ 1,900 $ 1,424

Basic income per share attributable to Perma-Fix Environmental Services, Inc. common stockholders $ .25 $ .02 $ .16 $ .12

Diluted income per share attributable to Perma-Fix Environmental Services, Inc. common stockholders $ .24 $ .02 $ .15 $ .12

Weighted average shares outstanding:
Basic weighted average shares outstanding 12,180 12,135 12,173 12,129
Add: dilutive effect of stock options 229 134 217 171
Add: dilutive effect of warrants 31 17 30 20
Diluted weighted average shares outstanding 12,440 12,286 12,420 12,320

Potential shares excluded from above weighted average share calcualtions due to their anti-dilutive effect include:
Stock options 12 38 36 38
Warrant — — — —
Stock Options and Warrants

		2022	2021
	Three Months Ended
	(Unaudited)
	March 31,
(Amounts in Thousands, Except for Per Share Amounts)	2022			2021
Net loss attributable to Perma-Fix Environmental Services, Inc., common stockholders:
Loss from continuing operations, net of taxes	$	(1,249	)	$	(1,038	)
Net loss attributable to non-controlling interest		—			(30	)
Loss from continuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders		(1,249	)		(1,008	)
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders		(94	)		(115	)
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(1,343	)	$	(1,123	)

Basic loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(.10	)	$	(.09	)

Diluted loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(.10	)	$	(.09	)

Weighted average shares outstanding:
Basic weighted average shares outstanding		13,234			12,165
Add: dilutive effect of stock options		—			—
Add: dilutive effect of warrants		—			—
Diluted weighted average shares outstanding		13,234			12,165

Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include:
Stock options		405			30
Warrant		—			—

8. ~~Long Term Debt~~

8.	Long Term Debt

Long-term debt consists of the following:

Schedule of Long ~~term~~Term Debt

(Amounts in Thousands)	June 30,2021			December 31, 2020			March 31, 2022			December 31, 2021
Total debt		1,223			6,729
Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2024. Effective interest rate for the first six month of 2021 was 5.3%. ⁽¹⁾	$	—		$	—
Term Loan dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2024. Effective interest rate for the first six months of 2021 was 4.4%. ⁽¹⁾		1,177	⁽²⁾		1,388	⁽²⁾
Promissory Note dated April 14, 2020, balance subject to loan forgiveness. Interest accrues at annual rate of 1.0%. ⁽³⁾		—	⁽⁴⁾		5,318	⁽⁴⁾
Notes Payable to 2023 and 2025, annual interest rate of 5.6% and 9.1%.		46			23
Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2024. Effective interest rate for first quarter of 2022 was 0%. ⁽¹⁾							$	—		$	—
Term Loan dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2024. Effective interest rate for the first quarter of 2022 was 4.3%. ⁽¹⁾								840	⁽²⁾		954	⁽²⁾
Notes Payable to 2023 and 2025, annual interest rate of 5.6% and 9.1%.								35			39
Total debt		1,223			6,729			875			993
Less current portion of long-term debt		404			3,595			384			393
Long-term debt	$	819		$	3,134		$	491		$	600

⁽¹⁾

Our revolving credit facility is collateralized by our accounts receivable and our term loan is collateralized by our property, plant, and equipment.

⁽²⁾

Net of debt issuance costs of ($~~103,000~~120,000) and ($~~105,000~~112,000) at ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

⁽³⁾	~~Uncollateralized note.~~14

⁽⁴⁾

Entered into with the Company’s credit facility lender under the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) (see “PPP Loan” below for information regarding forgiveness on the entire loan balance, along with accrued interest, effective June 15, 2021).

Revolving Credit and Term Loan Agreement

The Company entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020 (“Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The Loan Agreement provides the Company with the following credit facility with a maturity date of March 15, ~~2024:~~2024: (a) up to $18,000,000 revolving credit (“revolving credit”) and (b) a term loan (“term loan”) of approximately $1,742,000, requiring monthly installments of $35,547. The maximum that the Company can borrow under the revolving credit is based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that our lender may impose from time to time. The Loan Agreement, as amended, also provides a capital expenditure line of up to $1,000,000 with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during the Borrowing Period. At the end of the Borrowing Period, the total amount advanced under the line will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, as amended, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of March 31, 2022.

On ~~May 4, 2021,~~March 29, 2022, the Company entered into an amendment to ~~the~~its Loan Agreement with its lender which provided, ~~the following,~~ among other ~~things:~~things, the following:

●	●	~~revised~~waived the Company’s failure to meet the minimum quarterly fixed charge coverage ratio (“FCCR”) ~~calculation~~ requirement ~~which allows~~ for the ~~add-back~~fourth quarter of ~~approximately $5,318,000~~ in eligible expenses that were incurred and covered by the PPP Loan that the Company received in 2020. The add-back is to be applied retroactively to the second and third quarters of 2020. (see below for a discussion of the PPP Loan); and2021;
●	removes the quarterly FCCR testing requirement for the first quarter of 2022;
●	reinstates the quarterly FCCR testing requirement starting for the second quarter of 2022 and revises the methodology to be used in calculating the FCCR for the quarters ending June 30, 2022, September 30, 2022, and December 31, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter);
●	requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and certified to the lender; and
●	revises the annual rate used to calculate the Facility Fee (as defined in the Loan Agreement) on the revolving credit, with addition of the capital expenditure line, from 0.375% to 0.500%. Upon meeting the minimum FCCR requirement of ~~up to $1,000,000with advances~~1.15:1 on ~~the line, subject to certain limitations, permitted for up to~~a twelve months ~~starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during~~trailing basis, the ~~Borrowing Period (see annual~~Facility Fee rate of ~~interest below on the capital expenditure line). At the end of the Borrowing Period, the total amount advanced under the line~~0.375% will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of June 30, 2021.be reinstated.

In connection with the amendment, ~~the Company~~we paid ~~its lender~~PNC a fee of $1515,000~~,000~~ which is being amortized over the remaining term of the Loan Agreement, as amended, as interest expense-financing fees.

Pursuant to the Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit is at prime (~~3.25%~~3.50% at ~~June 30, 2021)~~March 31, 2022) plus 2%2% or ~~London InterBank Offer Rate (“LIBOR”)~~LIBOR plus ~~3.00%~~3.00% and the term loan and the capital expenditure line at prime plus ~~2.50%~~2.50% or LIBOR plus ~~3.50%~~3.50%. Under the LIBOR option of interest payment, a LIBOR floor of ~~0.75%~~0.75% applies in the event that LIBOR falls below ~~0.75%~~0.75% at any point in time.

The Company may terminate its Loan Agreement, as amended, upon 90 days’ prior written notice upon payment in full of our obligations under the Loan Agreement. The Company has agreed to pay PNC ~~1.0%~~ ~~of the total financing had the Company paid off its obligations on or before May 7, 2021 and~~ 0.5% of the total financing if ~~the Company~~it pays off its obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee will apply if the Company pays off its obligations under the Loan Agreement after May 7, 2022.

At ~~June 30, 2021,~~March 31, 2022, the borrowing availability under the Company’s revolving credit was approximately $~~9,550,000~~4,544,000 based on our eligible receivables and includes a reduction in borrowing availability of approximately $3,020,000 from outstanding standby letters of credit.

The Company’s credit facility under its Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under ~~the~~our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company ~~met its financial covenant requirements~~was not required to perform testing of the FCCR requirement in the first quarter of ~~2021. The Company’s FCCR calculation in the first quarter of 2021 included the add-back of approximately $5,318,000~~ ~~in eligible expenses that were incurred and covered by the PPP Loan that the Company received in 2020 as permitted by the amendment dated May 4, 2021~~2022 pursuant to the ~~Company’s Loan Agreement~~March 29, 2022 amendment as discussed ~~above. The Company did not meet~~above, otherwise, it met all of its FCCR requirement in the second quarter of 2021. However, this FCCR non-compliance was waived by the Company’s lender pursuant to another amendment dated August 10, 2021 to the Company’s Loan Agreement (see “Note 15 – Subsequent Events – Credit Facility” for a discussion of this waiver and additional provisions of this amendment).other financial covenant requirements.

~~PPP Loan~~

9.	Commitments and Contingencies

~~On April 14, 2020, the Company entered into a promissory note under the PPP with PNC, our credit facility lender, which had a balance of approximately $5,318,000~~ (the “PPP Loan”) at March 31, 2021. The PPP was established under the CARES Act and is administered by the U.S. Small Business Administration (“SBA”). The CARES Act was subsequently amended by the Paycheck Protection Program Flexibility Act of 2020 (“Flexibility Act”). Proceeds from the promissory note was used by the Company for eligible payroll costs, mortgage interest, rent and utility costs as permitted under the Flexibility Act. The annual interest rate on the PPP Loan is ~~1.0%~~

On October 5, 2020, the Company applied for forgiveness on repayment of the PPP Loan as permitted under the Flexibility Act. On July 1, 2021, the Company was notified by PNC that the entire balance of the PPP Loan of approximately $~~5,318,000, along with accrued interest of approximately $63,000~~ ~~was forgiven by the SBA, effective June 15, 2021. Accordingly, the Company recorded the entire forgiven PPP Loan balance, along with accrued interest, totaling approximately $5,381,000 as “Gain on extinguishment of debt” on its Consolidated Statement of Operations for the quarter ended June 30, 2021.~~

9. ~~Commitments and Contingencies~~

Hazardous Waste

In connection with our waste management services, the Company processes both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required at the disposal site, the Company could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.

Legal Matters

In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that could would have a material adverse effect on our financial position, liquidity or results of future operations.

Tetra Tech EC, Inc. (“Tetra Tech”)

During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the United States District Court for the Northern District of California (the “Court”) against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“Defendants”). The complaint alleges various claims, including a claim for negligence, negligent misrepresentation, ~~and~~ equitable indemnification and related business claims against all defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.

CH2M was hired by the Navy in 2016 to review Tetra Tech’s work. CH2M subcontracted with environmental consulting and cleanup firms Battelle Memorial Institute, Cabrera Services, Inc., SC&A, Inc. and the Company to assist with the review, according to the complaint.

The complaint alleges that the subject draft reports were prepared negligently and in a biased manner, made public, and caused damage to Tetra Tech’s reputation; triggering related lawsuits and costing it opportunities for both government and commercial contracts.

~~The Company has provided notice of this lawsuit to our insurance carrier.~~ Our insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a $~~100,000~~$100,000 self-insured retention and the terms and limitations contained in the insurance policy.

On January 7, 2021, Defendants’ motion to dismiss the complaint in its entirety was granted without prejudice, with leave to amend. Tetra Tech subsequently filed a First Amended Complaint (“FAC”) and Defendants filed a motion to dismiss Tetra Tech’s ~~FAC.~~FAC (the “Motion”). Tetra Tech filed an opposition to Defendant’s motion to dismiss Tetra Tech’s FAC. Defendants subsequently filed a joint reply to Tetra Tech’s motion in opposition. ~~A decision~~On January 27, 2022, the Motion was granted in part and ~~Order on Defendants’ motion to dismiss is pending from~~denied in part by the Court. ~~At this time,~~Tetra Tech’s claims for: (1) Negligence; (2) Equitable Indemnification/Contribution; and (3) Unfair Business Practices were dismissed. Tetra Tech was given leave to re-assert the Unfair Business Practices claim but chose not to do so, which means that claim is now also dismissed. Tetra Tech’s claims that survived the Motion are: (1) Intentional Interference with Contractual Relations; and (2) Inducing a Breach of Contract. The Company continues to believe it does not have any liability to Tetra Tech.

Perma-Fix Canada, Inc. (“PF Canada”)

During the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from Canadian Nuclear Laboratories, LTD. (“CNL”) on a Task Order Agreement (“TOA”) that PF Canada entered into with CNL in May 2019 for remediation work within Ontario, Canada (“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has since been completed. CNL may terminate the TOA at any time for convenience. As of March 31, 2022, PF Canada has approximately $2,722,000 in unpaid receivables and unbilled costs due from CNL as a result of work performed under the TOA. Additionally, CNL has approximately $1,150,000 in contractual holdback under the TOA that is payable to PF Canada. CNL also established a bond securing approximately $1,900,000 (CAD) to cover certain issue raised in connection with the TOA. Under the TOA, CNL may be entitled to set off certain costs and expenses incurred by CNL in connection with the termination of the TOA, including the bond as discussed above, against amounts owed to PF Canada for work performed by PF Canada or its subcontractors. PF Canada continues to be in discussions with CNL to finalize the amounts due to PF Canada under the TOA and continues to believes these amounts are due and payable.

Insurance

The Company has a 25-year finite risk insurance policy entered into in June 2003 (“2003 Closure Policy”) with AIG Specialty Insurance Company (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The 2003 Closure Policy, as amended, provides for a maximum allowable coverage of $28,177,000 which includes available capacity to allow for annual inflation and other performance and surety bond requirements. Total coverage under the 2003 Closure Policy, as amended, was $~~19,898,000~~21,047,000 at ~~June 30, 2021.~~March 31, 2022. At ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, finite risk sinking funds contributed by the Company related to the 2003 Closure Policy which is included in other long term assets on the accompanying Consolidated Balance Sheets totaled $~~11,467,000~~11,482,000 and $~~11,446,000~~11,471,000, respectively, which included interest earned of $~~1,996,000~~2,011,000 and $~~1,975,000~~2,000,000 on the finite risk sinking funds as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively. Interest income for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 was approximately $~~2,000~~11,000 and $~~21,000, respectively. Interest income for the three and six months ended June 30, 2020 was approximately $27,000~~ ~~and $83,000~~18,000, respectively. If we so elect, AIG is obligated to pay ~~the Company~~us an amount equal to ~~100%~~100% of the finite risk sinking fund account balance in return for complete release of liability from both ~~the Company~~us and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.

Letter of Credits and Bonding Requirements

From time to time, the Company is required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At ~~June 30, 2021,~~March 31, 2022, the total amount of standby letters of credit outstanding was approximately $3,020,000 and the total amount of bonds outstanding was approximately $~~43,561,000~~51,295,000.

1710.

Discontinued Operations

~~10.~~ ~~Discontinued Operations~~

The Company’s discontinued operations consist of all our subsidiaries included in our previous Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.

The Company’s discontinued operations had net losses of $~~127~~94,000~~,000~~ (net of tax benefit of $63,000) and $85115,000~~,000~~ (net of taxes of $0) for the three months ended ~~June 30, 2021~~March 31, 2022 and ~~2020, respectively (net of taxes of $~~0 ~~for each period) and net losses of $242,000 and $199,000 for the six months ended June 30, 2021 and 2020, respectively, (net of taxes of $~~0 ~~for each period).~~2021. The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. The Company’s discontinued operations had no revenues for each of the periods noted above.

The following table presents the major class of assets of discontinued operations as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021. No assets and liabilities were held for sale at each of the periods noted.

Schedule of Disposal Groups, Including Discontinued Operation Balance Sheet

	June 30,		December 31,		March 31,		December 31,
(Amounts in Thousands)	2021		2020		2022		2021
Current assets
Other assets	$	17	$	22	$	27	$	15
Total current assets		17		22		27		15
Long-term assets
Property, plant and equipment, net ⁽¹⁾		81		81		81		81
Other assets		—		—
Total long-term assets		81		81		81		81
Total assets	$	98	$	103	$	108	$	96
Current liabilities
Accounts payable	$	4	$	4	$	34	$	3
Accrued expenses and other liabilities		142		150		147		154
Environmental liabilities		671		744		621		349
Total current liabilities		817		898		802		506
Long-term liabilities
Closure liabilities		146		142		153		150
Environmental liabilities		110		110		255		527
Total long-term liabilities		256		252		408		677
Total liabilities	$	1,073	$	1,150	$	1,210	$	1,183

⁽¹⁾

net of accumulated depreciation of $10,000 for each period presented.

~~11.~~ ~~Operating Segments~~

11.	Operating Segments

In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.

Our reporting segments are defined as below:

TREATMENT SEGMENT, which includes:

	-	nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and

	-	~~Research & Development (“~~R~~&D”)~~&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.

SERVICES SEGMENT, which includes:

Technical services, which include:

	○	professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
	○	~~health physics services including health physicists, radiological engineers, nuclear engineers and health physics technicians support to government and private radioactive materials licensees;~~
	○	integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
	○	global technical services providing consulting, engineering, ~~(civil, nuclear, mechanical, chemical, radiological and environmental),~~ project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
	○	on-site waste management services to commercial and governmental customers.

Nuclear services, which include:

	○	technology-based services including engineering, decontamination and decommissioning (“D&D”) ~~of government~~, specialty services and ~~commercial facilities impacted with radioactive material and hazardous constituents including engineering, technology applications, specialty services,~~construction, logistics, transportation, processing and disposal;
	○	~~license termination support~~remediation of ~~radioactive material~~nuclear licensed and federal facilities ~~over~~and the ~~entire cycle~~remediation cleanup of ~~the termination process:~~nuclear legacy sites. Such services capability includes: project ~~management, planning, characterization, waste stream identification~~investigation; radiological engineering; partial and ~~delineation, remediation/demo, final status survey, compliance demonstration, reporting, transportation, disposal~~total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency ~~response.~~response; and

	-	A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
	-	~~A company owned gamma spectroscopy laboratory for the analysis of oil and gas industry solids and liquids.~~

~~MEDICAL SEGMENT, which is currently~~The Company’s segment also included the Medical Segment in 2021. As previously discussed, the Company made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of its interest in PFM Poland (which comprised the Medical Segment) in December 2021. The Company’s Medical Segment had not generated any revenue and was involved ~~on a limited basis~~ in ~~the R&D of~~ the Company’s medical isotope production technology, has not generated any revenue and has substantially reduced its R&D costs and activities due to the need for capital to fund these activities. The Company anticipates that the Medical Segment will not resume full R&D activities until the necessary capital is obtained through its own credit facility or additional equity raise, or obtains partners willing to provide funding for its R&D.technology.

Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues.

The table below presents certain financial information of our operating segments for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ (in thousands):

~~Schedule of Segment Reporting Information~~

~~Segment Reporting for the Quarter Ended June 30, 2021~~

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 7,706 $ 8,439 — $ 16,145 $ — $ 16,145
Intercompany revenues 319 32 — 351 — —
Gross profit (negative gross profit) 1,433 (467 ) — 966 — 966
Research and development 43 19 72 134 10 144
Interest income — — — — 2 2
Interest expense (18 ) — — (18 ) (47 ) (65 )
Interest expense-financing fees — — — — (9 ) (9 )
Depreciation and amortization 310 85 — 395 5 400
Segment income (loss) before income taxes 471 (1,292 ) (72 ) (893 ) 4,027 ⁽²⁾ 3,134
Income tax expense 3 10 — 13 — 13
Segment income (loss) 468 (1,302 ) (72 ) (906 ) 4,027 3,121
Expenditures for segment assets 270 10 — 280 9 289 ⁽³⁾

Segment Reporting for the Quarter Ended ~~June 30, 2020~~March 31, 2022

Schedule of Segment Reporting Information

		Treatment		Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total			Treatment			Services			Segments Total			Corporate⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,840		$	14,207			—		$	22,047		$	—		$	22,047		$	7,479		$	8,436		$	15,915		$	—		$	15,915
Intercompany revenues		446			5			—			451			—			—			111			183			294			—			—
Gross profit		1,695			1,615			—			3,310			—			3,310			638			998			1,636			—			1,636
Research and development		52			46			74			172			37			209			65			14			79			17			96
Interest income		1			—			—			1			27			28			—			—			—			11			11
Interest expense		(28	)		(4	)		—			(32	)		(67	)		(99	)		(14	)		(1	)		(15	)		(20	)		(35	)
Interest expense-financing fees		—			—			—			—			(60	)		(60	)		—			—			—			(13	)		(13	)
Depreciation and amortization		275			84			—			359			5			364			371			71			442			14			456
Segment income (loss) before income taxes		750			1,031			(74	)		1,707			(1,456	)		251
Segment (loss) income before income taxes																				(481	)		285			(196	)		(1,726	)		(1,922	)
Income tax benefit		(9	)		—			—			(9	)		—			(9	)		(559	)		(114	)		(673	)		—			(673	)
Segment income (loss)		759			1,031			(74	)		1,716			(1,456	)		260			78			399			477			(1,726	)		(1,249	)
Expenditures for segment assets		320			146			—			466			2			468	⁽⁴⁾		296			49			345			—			345	⁽²⁾

Segment Reporting for the ~~Six Months~~Quarter Ended ~~June 30,~~March 31, 2021

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 15,201 $ 24,077 — $ 39,278 $ — $ 39,278
Intercompany revenues 979 39 — 1,018 — —
Gross profit 2,358 964 — 3,322 — 3,322
Research and development 90 32 149 271 24 295
Interest income — — — — 21 21
Interest expense (37 ) (8 ) — (45 ) (87 ) (132 )
Interest expense-financing fees — — — — (17 ) (17 )
Depreciation and amortization 620 170 — 790 9 799
Segment income (loss) before income taxes 352 (737 ) (149 ) (534 ) 2,613 ⁽²⁾ 2,079
Income tax (benefit) expense (14 ) 10 — (4 ) — (4 )
Segment income (loss) 366 (747 ) (149 ) (530 ) 2,613 2,083
Expenditures for segment assets 627 14 — 641 9 650 ⁽³⁾

	Treatment			Services			Medical			Segments Total			Corporate⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,495		$	15,638		$	—		$	23,133		$	—		$	23,133
Intercompany revenues		660			7			—			667			—			—
Gross profit		925			1,431			—			2,356			—			2,356
Research and development		47			13			76			136			14			150
Interest income		—			—			—			—			18			18
Interest expense		(19	)		(8	)		—			(27	)		(40	)		(67	)
Interest expense-financing fees		—			—			—			—			(8	)		(8	)
Depreciation and amortization		310			85			—			395			5			400
Segment (loss) income before income taxes		(119	)		555			(76	)		360			(1,415	)		(1,055	)
Income tax benefit		(17	)		—			—			(17	)		—			(17	)
Segment (loss) income		(102	)		555			(76	)		377			(1,415	)		(1,038	)
Expenditures for segment assets		357			4			—			361			—			361	⁽²⁾

~~Segment Reporting for the Six Months Ended June 30, 2020~~

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 17,403 $ 29,504 — $ 46,907 $ — $ 46,907
Intercompany revenues 653 13 — 666 — —
Gross profit 4,440 3,510 — 7,950 — 7,950
Research and development 145 112 140 397 44 441
Interest income 1 — — 1 83 84
Interest expense (46 ) (10 ) — (56 ) (163 ) (219 )
Interest expense-financing fees — — — — (129 ) (129 )
Depreciation and amortization 539 162 — 701 10 711
Segment income (loss) before income taxes 2,297 2,349 (140 ) 4,506 (2,933 ) 1,573
Income tax expense 5 — — 5 — 5
Segment income (loss) 2,292 2,349 (140 ) 4,501 (2,933 ) 1,568
Expenditures for segment assets 1,000 361 — 1,361 5 1,366 ⁽⁴⁾

⁽¹⁾

Amounts reflect the activity for corporate headquarters not included in the segment information.


⁽²⁾	~~Amounts includes approximately $5,381~~,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).

⁽³⁾	Net of financed amount of $0114,000 and $29,000 for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~respectively.~~

⁽⁴⁾	~~Net of financed amount of $51,000~~ ~~and $132,000~~ ~~for the three and six months ended June 30, 2020,~~ respectively.

2019

~~12.~~ ~~Income Taxes~~

12.

Income Taxes

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.

The Company had income tax ~~expense of $~~13~~,000 and income tax~~ benefit of approximately $4673,000~~,000~~ for continuing operations for the three ~~and six~~ months ended ~~June 30, 2021, respectively, and~~March 31, 2022 as compared to income tax benefit of approximately $917,000~~,000 and income tax expense of $~~5~~,000~~ for continuing operations for the three ~~and six~~ months ended ~~June 30, 2020, respectively.~~March 31, 2021. The Company’s effective tax ~~rates were~~rate was approximately ~~0.4%~~35.0% and ~~0.2%~~1.6% for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and the corresponding period of 2021, ~~respectively, and~~ ~~3.6%~~ ~~and~~ ~~0.3%~~ ~~for the three and six months ended June 30, 2020,~~ respectively. The Company’s tax rate for ~~each of~~ the ~~periods discussed above~~three months ended March 31, 2022 was impacted by non-deductible expenses and state taxes. The Company’s tax rate for the three months ended March 31, 2021 was impacted by non-deductible expenses, state taxes, and by the Company’s full valuation on its net deferred tax ~~assets.~~assets which was subsequently released partially in the third quarter of 2021.

13.

Variable Interest Entities (“VIE”)

~~13.~~ ~~Variable Interest Entities (“VIE”)~~

The Company and Engineering/Remediation Resources Group, Inc. (“ERRG”) previously entered into an unpopulated joint venture agreement for project work bids within the Company’s Services Segment with the joint venture doing business as Perma-Fix ERRG, a general partnership. The Company has a ~~51%~~51% partnership interest in the joint venture and ERRG has a ~~49%~~49% partnership interest in the joint venture.

The Company determines whether joint ventures in which it has invested meet the criteria of a VIE at the start of each new venture and when a reconsideration event has occurred. A VIE is a legal entity that satisfies any of the following characteristics: (a) the legal entity does not have sufficient equity investment at risk; (b) the equity investors at risk as a group, lack the characteristics of a controlling financial interest; or (c) the legal entity is structured with disproportionate voting rights.

The Company consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

Based on the Company’s evaluation of Perma-Fix ERRG and related agreements with Perma-Fix ERRG, the Company determined that Perma-Fix ERRG continues to be a VIE in which ~~the Company is~~we are the primary beneficiary. At ~~June 30, 2021,~~March 31, 2022, Perma-Fix ERRG had total assets of $~~2,528~~122,000~~,000~~ and total liabilities of approximately $~~2,528~~122,000~~,000~~ which are all recorded as current.

~~14.~~ ~~Deferral of Employment Tax Deposits~~
14. Executive Compensation

The Company’s Compensation Committee and the Board determined that no performance payment would be made to each executive officer under his 2021 Management Incentive Plan (“MIP”). In lieu of any performance payment to each executive officer under his 2021 MIP and in an attempt to retain the executive officer, on January 20, 2022, the Compensation Committee and the Board determined that the base annual compensation for each executive officer for 2022 is increased by approximately 6.4%, effective January 1, 2022, to offset the cost-of-living increase.

On January 20, 2022, the Board and the Compensation Committee also approved individual MIP for the calendar year 2022 for each of our executive officers. Each MIP is effective January 1, 2022 and applicable for year 2022. Each MIP provides guidelines for the calculation of annual cash incentive-based compensation, subject to Compensation Committee oversight and modification. The ~~Flexibility Act provides employers the option to defer the payment of an employer’s share of social security taxes beginning on March 27, 2020 through December 31, 2020 with~~ ~~50%~~performance compensation under each of the ~~amount~~MIPs is based upon meeting certain of ~~social security taxes deferred to become due on December 31, 2021 with the remaining~~ ~~50%~~ ~~due on December 31, 2022. The Company elected to defer such taxes starting in mid-April 2020. At June 30, 2021, the Company has deferred payment of approximately $1,252,000~~ ~~in its share of social security taxes, of which approximately $626,000 is included in “Other long-term liabilities,” with the remaining balance included in “Accrued expenses” within current liabilities in~~ the Company’s ~~Consolidated Balance Sheets.~~separate target objectives during 2022. Assuming each target objective is achieved under the same performance threshold range under each MIP, the total potential target performance compensation payable ranges from 25% to 150% of the 2022 base salary for the CEO ($93,717 to $562,304), 25% to 100% of the 2022 base salary for the CFO ($76,193 to $304,772), 25% to 100% of the 2022 base salary for the EVP of Strategic Initiatives ($63,495 to $253,980), 25% to 100% of the 2022 base salary for the EVP of Nuclear and Technical Services ($76,193 to $304,772) and 25% to 100% ($65,308 to $261,233) of the 2022 base salary for the EVP of Waste Treatment Operations.

2115.

Subsequent Events

~~15.~~ ~~Subsequent Events~~

Management evaluated events occurring subsequent to ~~June 30, 2021~~March 31, 2022 through ~~August 11, 2021,~~May 5, 2022, the date these consolidated financial statements were available for issuance, and ~~other than as noted below~~ determined that no material recognizable subsequent events occurred.

~~2003 Plan~~

During April 2021, the Company’s Board approved an amendment to the 2003 Plan which was approved by the Company’s Shareholders at the Company’s Annual Meeting of Stockholders held on July 20, 2021 (the “Meeting”). The amendment provides, among other things, the following:

Item 2.	●	~~The number~~Management’s Discussion and Analysis of ~~shares~~Financial Condition and Results of ~~Common Stock available for issuance under the 2003 Plan was increased by an additional~~ ~~500,000~~ ~~shares;~~
	●	~~Each outside director is to be granted an option to purchase up to~~ ~~10,000~~ ~~shares of Common Stock on each date the director is reelected to the Board;~~
	●	~~Each newly-elected outside director is to be granted an option to purchase up to~~ ~~20,000~~ ~~shares of Common Stock upon initial election to the Board; and~~
	●	~~Changes to the vesting schedule of each option granted under the 2003 Plan to outside directors.~~Operations

Upon the approval of the amendment to the 2003 Plan as discussed above and upon the reelection of the Company’s seven outside directors at the Meeting, the Company issued a NQSO to each of the Company’s seven reelected outside directors for the purchase of up to ~~10,000~~ shares of the Company’s Common Stock. Dr. Louis Centofanti, the Company’s EVP of Strategic Initiatives and also a director, was not eligible to receive an option under the 2003 Plan as an employee of the Company. Each NQSO granted was for a contractual term of ten years with one-fourth vesting annually over a four year period. The exercise price of the NQSO was $~~5.93~~ ~~per share, which was equal to the fair market value of the Company’s Common Stock the day preceding the grant date, pursuant to the 2003 Plan.~~

~~Credit Facility~~

~~On August 10, 2021, the Company entered into an amendment to its Loan Agreement with its lender which provided, among other things, the following:~~

	●	~~waived the Company’s failure to meet the minimum quarterly FCCR requirement for the second quarter of 2021;~~
	●	~~removes the quarterly FCCR testing requirement for the third quarter of 2021;~~
	●	~~reinstates~~ the quarterly FCCR testing requirement starting for the fourth quarter of 2021 and revises the methodology to be used in calculating the FCCR for the quarters ending December 31, 2021, March 31, 2022, and June 30, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter)~~; and~~
	●	~~requires maintenance of a minimum $3,000,000~~ ~~in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended December 31, 2021 has been met and certified to the lender.~~

~~In connection with the amendment, the Company paid its lender a fee of $15,000. All other terms of the Loan Agreement remains principally unchanged.~~

~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations~~

Forward-looking Statements

Certain statements contained within this report may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the “Private Securities Litigation Reform Act of 1995”). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words “believe,” “expect,” “anticipate,” “intend,” “will,” and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,

●	demand for our services;
●	reductions in the level of government funding in future years;
●	~~R&D activity and necessary capital of our Medical Segment;~~
●	reducing operating costs and non-essential expenditures;
●	ability to meet loan agreement quarterly covenant requirements;
●	cash flow requirements;
●	~~accounts receivable impact and collections;~~Canadian receivable;
●	sufficient liquidity to continue business;
●	future results of operations and liquidity;
●	effect of economic disruptions on our business;
●	~~curtail capital expenditures;~~
●	government funding for our services;
●	may not have liquidity to repay debt if our lender accelerates payment of our borrowings;
●	deployment of unit;
●	manner in which the applicable government will be required to spend funding to remediate various sites;
●	funding operations;
●	continued increases in pricing and/or further tightening supply chain;
●	fund capital expenditures from cash from operations and/or financing;
●	impact from ~~COVID-19;~~COVID-19 and impact from other delays;
●	~~procurement actions and contract awards;~~
●	~~waste receipts and contract awards in the second half of 2021;~~
●	~~returns~~improvement in waste shipments;
●	fund remediation expenditures for sites from funds generated internally;
●	collection of accounts receivables;
●	compliance with environmental regulations;
●	potential effect of being a PRP;
●	potential sites for violations of environmental laws and remediation of our facilities;

●	remediation of material weakness;
●	future price increases; and
●	continuation of contracts with federal ~~government;~~
●	~~partial or full shutdown of any of our facilities;~~
●	~~continued waste shipments delays by clients; and~~
●	~~R&D costs.~~government.

While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:

●	general economic conditions;
●	contract bids, including international markets;
●	material reduction in revenues;
●	inability to meet PNC covenant requirements;
●	inability to collect in a timely manner a material amount of receivables;

●	increased competitive pressures;
●	inability to maintain and obtain required permits and approvals to conduct operations;
●	public not accepting our new technology;
●	inability to develop new and existing technologies in the conduct of operations;
●	inability to maintain and obtain closure and operating insurance requirements;
●	inability to retain or renew certain required permits;
●	discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures;
●	delays at our third-party disposal site can extend collection of our receivables greater than twelve months;
●	refusal of third-party disposal sites to accept our waste;
●	changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such;
●	requirements to obtain permits for TSD activities or licensing requirements to handle low level radioactive materials are limited or lessened;
●	potential increases in equipment, maintenance, operating or labor costs;
●	management retention and development;
●	financial valuation of intangible assets is substantially more/less than expected;
●	the requirement to use internally generated funds for purposes not presently anticipated;
●	inability to continue to be profitable on an annualized basis;
●	inability of the Company to maintain the listing of its Common Stock on the NASDAQ;
●	terminations of contracts with government agencies ~~(domestic and foreign)~~ or subcontracts involving government agencies ~~(domestic or foreign),~~ or reduction in amount of waste delivered to the Company under the contracts or subcontracts;
●	renegotiation of contracts involving government ~~agencies (domestic and foreign);~~agencies;
●	federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites;
●	disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment;
●	inability to raise capital on commercially reasonable terms;
●	inability to increase profitable revenue;
●	impact of the COVID-19;
●	delays in waste shipments and ~~contract awards;~~delay in activities under new contracts;
●	new governmental regulations;
●	lender refuses to waive non-compliance or revise our covenant so that we are in compliance;
●	continued supply chain interruptions;
●	continued inflationary pressures;
●	other unanticipated factors; and
●	risk factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s ~~2020~~2021 Form 10-K and the “Forward-Looking Statements” contained in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) of ~~the~~this first quarter ~~2021 Form 10-Q and this second quarter 2021~~2022 Form 10-Q.

COVID-19 Impact and Impact due to Other Delays

Our ~~management team continues~~first quarter financial results continued to ~~proactively update our ongoing business operations and safety plans in an effort to mitigate any potential impact of~~be impacted by COVID-19. We continue to remain focused on protecting the health and well-being of our employees and the communities in which we operate while assuring the continuity of our business operations, particularly in light of emerging new variants of the virus. Similar to most of the U.S., we have relaxed COVID-19 precautions associated with operations since more people have become vaccinated, including our employees. However, our Treatment Segment continues to see unexpected delays in waste shipments from certain customers due to impacts of COVID-19. We expect to see returns in waste receipts from these customers starting in the second half of 2021. WithinAs previously disclosed, within our Services Segment, we ~~continue to experience~~experienced delays in procurement actions and contract awards during the first half of 2021 resulting ~~primarily~~ from the impact of COVID-19. Since the end of the second quarter of 2021, we were awarded a number of new contracts. However, due to continued COVID-19 ~~but~~impact and/or customer administrative delay experienced by certain customers, work under certain of our new awards was temporarily curtailed/delayed which continued for most of the first quarter of 2022 and negatively impacted revenue. We have, ~~recently~~however, begun to ~~receive~~see improvement in activities from certain of these new ~~contract awards.~~projects starting in the latter part of the first quarter of 2022. Our Treatment Segment revenue continues to be negatively impacted by continued waste shipment delays from certain customers since the latter part of the first quarter of 2020, the start of the pandemic. We expect to see a gradual improvement in waste receipts from these customers in the upcoming months as our customers start easing up on COVID-19 restrictions; however, such may not be the case based on our customers’ own responses to COVID-19, including, but not limited to delaying or limiting full return-to-work schedules. Additionally, as a result of supply chain challenges, we experienced a delay in the delivery of a new technology waste processing unit from our supplier which negatively impacted our revenue as associated revenue was not able to be generated. Delivery of this unit had been expected during the third quarter of 2021 but did not occur until the latter part of the first quarter of 2022. Deployment of this unit is expected to commence in the second quarter of 2022. Within our Treatment ~~and Services Segments,~~Segment, we are experiencing a large increase in proposal requests. We continue to have ~~an unprecedented number of~~ bids currently submitted in both segments and awaiting awards. ~~We expect procurement actions and contract awards to continue throughout the second half of 2021.~~

At this time, we believe we have sufficient liquidity on hand to continue business operations during the next twelve months. At March 31, 2022, we had borrowing availability under our revolving credit facility of approximately $4,544,000 which was based on a percentage of eligible receivables and subject to certain reserves. As a result of a recent amendment to our Loan Agreement, we are required to maintain a minimum of $3,000,000 in borrowing availability under our revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and certified to our lender (see “Financing Activities” within this MD&A for a discussion of this amendment). We continue to assess the need in reducing operating costs during this volatile time, which may include curtailing certain capital expenditures and eliminating non-essential expenditures.

We are closely monitoring our customers’ payment performance. However, since a significant portion of our revenues is derived from government related contracts, we do not expect our accounts receivable collections to be materially impacted due to COVID-19.

As the situations surrounding COVID-19 continues to remain fluid, the full impact and extent of the pandemic on our financial results and liquidity cannot be estimated with any degree of certainty. We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including supply chain challenges, our ~~customers’ payment performance. However, since a significant portion of our revenues is derived~~labor force and increasing costs from ~~government related contracts, we do not expect our accounts receivable collections to be materially impacted due to COVID-19.~~inflationary pressures (see “Known Trends and Uncertainties” – “Supply Chain” and “Inflation and Cost Increases” within this MD&A).

At this time, we believe we have sufficient liquidity on hand to continue business operations during the next twelve months. At June 30, 2021, our borrowing availability under our revolving credit facility was approximately $9,550,000 which was based on a percentage of eligible receivables and subject to certain reserves. We continue to assess the need in reducing operating costs during this volatile time, which may include curtailing capital expenditures, eliminating non-essential expenditures and implementing a hiring freeze as needed. Based on our current projection, we believe that we will be able to meet our current covenant requirements under our loan agreement for the next twelve months, however, such may not be the case due to, among other things, the uncertainty of COVID on our operations and/or delays in procurement actions, contract awards, or waste shipments.

Overview

~~Our overall revenue~~Revenue decreased ~~$5,902,000~~by $7,218,000 or ~~26.8%~~31.2% to ~~$16,145,000~~$15,915,000 for the three months ended ~~June 30, 2021~~March 31, 2022 from ~~$22,047,000~~$23,133,000 for the corresponding period of ~~2020 due primarily from the impact of COVID-19.~~2021. The ~~revenue~~ decrease was primarily within our Services Segment where revenue decreased byto $8,436,000 from $15,638,000 or approximately ~~$5,768,000 or 40.6%~~46.1%. As discussed above, work under certain of the new projects awarded to $8,439,000 for the three months ended June 30, 2021 from $14,207,000 for the corresponding period of 2020 primarily due to delays in procurement actions and contract awards resulting primarily from the impact of COVID-19. The completion of a certain large project in theour Services Segment inat the end of the second quarter ~~exacerbated~~of 2021 continued to be delayed/curtailed for most of the ~~decrease~~first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in ~~revenue. Revenue within our Treatment Segment decreased $134,000 or 1.7%. Our Treatment Segment’s revenue has been negatively impacted by continued waste shipment delays~~activities from certain ~~customers since~~of these new projects starting in the latter part of the first quarter of ~~2020 at~~2022. The lower revenue in the ~~start~~first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the ~~pandemic. However, we expect to see~~ ~~returns in waste receipts from these customers starting~~completion of a large project in the second quarter of 2021 which was not replaced with a similar size contract because of delays in contract awards and procurement from COVID-19 impact in the first half of 2021. Our Treatment Segment revenue decreased slightly by $16,000 or 0.2%. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has not returned to pre-pandemic levels as certain customers continue to delay waste shipments due to impact of COVID-19. Gross profit decreased ~~$2,344,000~~$720,000 or ~~70.8% primarily due to decreases in revenues in both segments as described above.~~30.6%. Selling, General, and Administrative (“SG&A”) expenses increased ~~by approximately 297,000~~$217,000 or ~~11.0%~~6.8% for the three months ended ~~June 30, 2021~~March 31, 2022 as compared to the corresponding period of ~~2020.~~2021.

Our overall revenue decreased $7,629,000 or 16.3% to $39,278,000 for the six months ended June 30, 2021 from $46,907,000 for the corresponding period of 2020. Services Segment revenue decreased by $5,427,000 or 18.4% to $24,077,000 for the six months ended June 30, 2021 from $29,504,000 for the corresponding period of 2020 primarily due to delays in procurement actions and contract awards as discussed above. Additionally, as discussed above, the completion of a certain large project in the Services Segment in the second quarter of 2021 exacerbated the decrease in revenue. Treatment Segment revenue decreased by $2,202,000 or 12.7% to $15,201,000 for the six months ended June 30, 2021 from $17,403,000 for the corresponding period of 2020 primarily due to continued delays in waste shipments from certain customers as discussed above. Total gross profit decreased $4,628,000 or 58.2% for the six months ended June 30, 2021 as compared to the corresponding period of 2020. Total SG&A expenses increased $575,000 or 10.2% for the six months ended June 30, 2021 as compared to the corresponding period of 2020.

Our working capital was $3,394,000 at June 30, 2021 as compared to working capital of $3,672,000 at December 31, 2020. Our working capital was negatively impacted by revenue decreases in both Segments. However, the forgiveness of our Paycheck Protection Program (“PPP”) Loan, along with accrued interest, by the U.S. Small Business Administration (“SBA”) had a positive impact to our working capital (see “The CARES Act – PPP Loan” within this MD&A for a discussion of this loan forgiveness).

Business Environment

Our Treatment and Services Segments’ business continues to be heavily dependent on services that we provide to governmental clients, primarily as subcontractors for others who are prime contractors to government entities or directly as the prime contractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without limitation, the economic conditions, the manner in which the applicable government will be required to spend funding to remediate various sites, and/or ~~the~~potential further impact ~~resulting~~ from ~~COVID-19 as discussed above.~~COVID-19. In addition, our governmental contracts and subcontracts relating to activities at governmental sites in the United States are generally subject to termination ~~or renegotiation on 30 days’ notice~~for convenience at any time at the government’s option, and our governmental contracts/task orders with the Canadian government authorities also allow the authorities to terminate the contract/task orders at any time for convenience. Our work under all of our contracts/task order agreements with Canadian government authorities has substantially been completed. See “Known Trends and Uncertainties – Perma-Fix Canada, Inc. (“PF Canada”)” for additional discussion as to a terminated Canadian TOA. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows. As previously disclosed, our Medical Segment has not generated any revenues and has substantially reduced its R&D costs and activities due to the need for capital to fund such activities. We anticipate that our Medical Segment will not resume full R&D activities until it obtains the necessary funding through obtaining its own credit facility or additional equity raise or obtaining new partners willing to fund its R&D activities. If the Medical Segment is unable to raise the necessary capital, the Medical Segment could be required to further reduce, delay or eliminate its R&D program.

We are continually reviewing methods to raise additional capital to supplement our liquidity requirements, when needed, and reducing our operating costs. We continue to aggressively bid on various contracts, including potential contracts within the international markets.

Results of Operations

The reporting of financial results and pertinent discussions are tailored to our ~~three~~two reportable segments: The Treatment ~~Services,~~ and Services. Our financial results for 2021 also included our Medical Segments. As previously disclosed, we made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of our interest in PFM Poland (which comprised the Medical Segment) in December 2021. Our Medical Segment ~~has~~had not generated any revenue and ~~all~~was involved in our medical isotope production technology. All costs previously incurred ~~are~~by the Medical Segment were included within R&D.

~~Summary – Three and Six Months Ended June 30, 2021 and 2020~~

Three Months Ended Six Months Ended
June 30, June 30,
Consolidated (amounts in thousands) 2021 % 2020 % 2021 % 2020 %
Net revenues $ 16,145 100.0 $ 22,047 100.0 $ 39,278 100.0 $ 46,907 100.0
Cost of goods sold 15,179 94.0 18,737 85.0 35,956 91.5 38,957 83.1
Gross profit 966 6.0 3,310 15.0 3,322 8.5 7,950 16.9
Selling, general and administrative 2,997 18.6 2,700 12.2 6,202 15.8 5,627 12.0
Research and development 144 .9 209 .9 295 .8 441 .9
(Gain) loss on disposal of property and equipment — — (4 ) — — — 27 —
(Loss) income from operations (2,175 ) (13.5 ) 405 1.9 (3,175 ) (8.1 ) 1,855 4.0
Interest income 2 — 28 .1 21 — 84 .2
Interest expense (65 ) (.4 ) (99 ) (.5 ) (132 ) (.3 ) (219 ) (.5 )
Interest expense-financing fees (9 ) — (60 ) (.3 ) (17 ) — (129 ) (.3 )
Other — — 4 — 1 — 9 —
Gain (loss) on extinuishment of debt 5,381 33.3 (27 ) (.1 ) 5,381 13.7 (27 ) —
Income from continuing operations before taxes 3,134 19.4 251 1.1 2,079 5.3 1,573 3.4
Income tax expense (benefit) 13 .1 (9 ) (.1 ) (4 ) — 5 —
Income (loss) from continuing operations $ 3,121 19.3 $ 260 1.2 $ 2,083 5.3 $ 1,568 3.4
2624

Summary – Three Months Ended March 31, 2022 and 2021
Three Months Ended
March 31,
Consolidated (amounts in thousands) 2022 % 2021 %
Revenues $ 15,915 100.0 $ 23,133 100.0
Cost of good sold 14,279 89.7 20,777 89.8
Gross profit 1,636 10.3 2,356 10.2
Selling, general and administrative 3,422 21.5 3,205 13.9
Research and development 96 .6 150 .6
Loss on disposal of property and equipment 1 — — —
Loss from operations $ (1,883 ) (11.8 ) $ (999 ) (4.3 )
Interest income 11 — 18 —
Interest expense (35 ) (.2 ) (67 ) (.2 )
Interest expense-financing fees (13 ) (.1 ) (8 ) —
Other (2 ) — 1 —
Loss from continuing operations before taxes (1,922 ) (12.1 ) (1,055 ) (4.5 )
Income tax benefit (673 ) (4.3 ) (17 ) —
Loss from continuing operations $ (1,249 ) (7.8 ) $ (1,038 ) (4.5 )
Revenues
Consolidated revenues decreased ~~$5,902,000~~$7,218,000 for the three months ended ~~June 30, 2021,~~March 31, 2022, compared to the three months ended ~~June 30, 2020,~~March 31, 2021, as follows:

(In thousands) 2021
%
Revenue
2020
%
Revenue
Change % Change 2022 % Revenue 2021 % Revenue Change % Change
Treatment
Government waste $ 5,102 31.6 $ 5,559 25.2 $ (457 ) (8.2 ) $ 5,437 34.2 $ 4,387 18.9 $ 1,050 23.9
Hazardous/non-hazardous ⁽¹⁾ 1,317 8.1 938 4.3 379 40.4 1,001 6.3 1,311 5.7 (310 ) (23.6 )
Other nuclear waste 1,287 8.0 1,343 6.1 (56 ) (4.2 ) 1,041 6.5 1,797 7.8 (756 ) (42.1 )
Total 7,706 47.7 7,840 35.6 (134 ) (1.7 ) 7,479 47.0 7,495 32.4 (16 ) (0.2 )

Services
Nuclear services 8,052 49.9 13,776 62.5 (5,724 ) (41.6 ) 8,281 52.0 15,080 65.2 (6,799 ) (45.1 )
Technical services 387 2.4 431 1.9 (44 ) (10.2 ) 155 1.0 558 2.4 (403 ) (72.2 )
Total 8,439 52.3 14,207 64.4 (5,768 ) (40.6 ) 8,436 53.0 15,638 67.6 (7,202 ) (46.1 )

Total $ 16,145 100.0 $ 22,047 100.0 $ (5,902 ) (26.8 ) $ 15,915 100.0 $ 23,133 100.0 $ (7,218 ) (31.2 )

¹⁾⁽¹⁾Includes wastes generated by government clients of ~~$544,000~~$470,000 and ~~$496,000~~$745,000 for the three ~~month~~months ended ~~June 30, 2021~~March 31, 2022 and the corresponding period of ~~2020,~~2021, respectively.

Treatment Segment revenue decreased ~~$134,000~~slightly by $16,000 or ~~1.7%~~0.2% for the three months ended ~~June 30, 2021~~March 31, 2022 over the same period in ~~2020.~~2021. The ~~revenue~~ decrease ~~was attributed primarily to lower revenue from government waste generators resulting from lower waste volume. The increase~~ in hazardous/~~non hazardous waste~~non-hazardous revenue was primarily due to ~~higher~~lower waste volume. Revenue from other nuclear waste was lower primarily due to lower averaged price waste. ~~Our~~Waste from government generators increased by approximately $1,050,000 or 23.9% primarily due higher waste volume. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has ~~been negatively impacted~~not returned to pre-pandemic levels as certain customers continue to delay waste shipments due, in part, to impact of COVID-19. Our Services Segment revenue decreased by approximately $7,202,000 or 46.1%. Work under certain of the new projects awarded to our Services Segment at the end of the second quarter of 2021 continued ~~waste shipment~~to be delayed/curtailed for most of the first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in activities from certain ~~customers since~~of these new projects starting in the latter part of the first quarter of ~~2020 at~~2022. The lower revenue in the ~~start~~first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the ~~COVID-19 pandemic. Services Segment revenue decreased by approximately $5,768,000 or 40.6%. As previously disclosed, our Services Segment revenue for~~completion of a large project in the second quarter of 2021 which was ~~impacted primarily by~~not replaced with a similar size contract from delays in ~~procurement actions and~~ contract awards ~~resulting~~and procurement from COVID-19 impact in the ~~impact~~first half of ~~COVID-19.~~2021. Our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.
~~Consolidated revenues decreased $7,629,000 for the six months ended June 30, 2021, as compared to the six months ended June 30, 2020, as follows:~~
(In thousands) 2021
%
Revenue
2020
%
Revenue
Change
%
Change

Treatment
Government waste $ 9,489 24.1 $ 12,626 26.9 $ (3,137 ) (24.8 )
Hazardous/non-hazardous ⁽¹⁾ 2,628 6.7 2,462 5.3 166 6.7
Other nuclear waste 3,084 7.9 2,315 4.9 769 33.2
Total 15,201 38.7 17,403 37.1 (2,202 ) (12.7 )

Services
Nuclear services 23,132 58.9 28,611 61.0 (5,479 ) (19.1 )
Technical services 945 2.4 893 1.9 52 5.8
Total 24,077 61.3 29,504 62.9 (5,427 ) (18.4 )

Total $ 39,278 100.0 $ 46,907 100.0 $ (7,629 ) (16.3 )
¹⁾~~Includes wastes generated by government clients of $1,289,000 and $1,119,000 for the six month ended June 30, 2021 and the corresponding period of 2020, respectively.~~
2725

Treatment Segment revenue decreased $2,202,000 or 12.7 % for the six months ended June 30, 2021 over the same period in 2020 primarily due to lower waste volume. As previously disclosed, since the latter part of the first quarter of 2020 at the start of the pandemic, revenue within our Treatment Segment has been impacted by waste shipment delays from certain customers primarily due to the impact of COVID-19. Within our Treatment Segment, revenue generated from other nuclear waste increased primarily due to higher waste volume generated from commercial customers. Services Segment revenue decreased $5,427,000 or 18.4% for the six months ended June 30, 2021 over the same period in 2020. As previously disclosed, our Services Segment revenue for the first six months of 2021 was impacted by delays in procurement actions and contract awards resulting primarily from the impact of COVID-19. Also, our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.
Cost of Goods Sold

Cost of goods sold decreased ~~$3,558,000~~$6,498,000 for the quarter ended ~~June 30, 2021, as~~March 31, 2022, compared to the quarter ended ~~June 30, 2020,~~March 31, 2021, as follows:

% % % %
(In thousands) 2021 Revenue 2020 Revenue Change 2022 Revenue 2021 Revenue Change
Treatment $ 6,273 81.4 $ 6,145 78.4 $ 128 $ 6,841 91.5 $ 6,570 87.7 $ 271
Services 8,906 105.5 12,592 88.6 (3,686 ) 7,438 88.2 14,207 90.8 (6,769 )
Total $ 15,179 94.0 $ 18,737 85.0 $ (3,558 ) $ 14,279 89.7 $ 20,777 89.8 $ (6,498 )

Cost of goods sold for the Treatment Segment increased by approximately ~~$128,000~~$271,000 or ~~2.1%~~4.1%. The increased costs was primarily due to higher overall fixed costs of approximately $277,000 resulting from the following: general expenses were higher by $144,000 primarily due to higher utility costs; salaries and payroll related expenses were higher by approximately $49,000; depreciation expenses were higher by approximately $59,000 due to depreciation for asset retirement obligations in connection with our EWOC facility; regulatory expenses were higher by approximately $15,000; and travel expenses were higher by $10,000 resulting from easing up of COVID-19 restrictions. Treatment Segment’s variable costs ~~increased~~decreased slightly by approximately ~~$136,000~~$6,000 primarily due to lower overall costs in disposal, transportation, material and supplies ~~and~~which were mostly offset by higher outside services. Treatment Segment’s overall fixed costs were slightly lower by approximately $8,000 resulting from the following: payroll related expenses were lower by approximately $54,000; maintenance expenses were lower by $54,000; general expenses were higher by $52,000 in various categories; depreciation expenses were higher by approximately $35,000 due to more financed leases; and travel expenses were higher by approximately $13,000 due to ease of travel restrictions since the start of the pandemic.services costs. Services Segment cost of goods sold decreased ~~$3,686,000~~approximately $6,769,000 or ~~29.3%~~47.6% primarily due to lower revenue. The decrease in cost of goods sold was primarily due to lower salaries/payroll related, travel, and outside services expenses totaling ~~approximately $3,177,000 with the remaining~~$6,909,000. The overall lower costs inwere partially offset by higher material and supplies ~~disposal, regulatory, and general expenses.~~costs. Included within cost of goods sold is depreciation and amortization expense of ~~$394,000~~$439,000 and ~~$358,000~~$394,000 for the three months ended ~~June 30,~~March 31, 2022, and 2021, ~~and 2020,~~ respectively.

~~Cost of goods sold decreased $3,001,000 for the six months ended June 30, 2021, as compared to the six months ended June 30, 2020, as follows:~~
% %
(In thousands) 2021 Revenue 2020 Revenue Change
Treatment $ 12,843 84.5 $ 12,963 74.5 $ (120 )
Services 23,113 96.0 25,994 88.1 (2,881 )
Total $ 35,956 91.5 $ 38,957 83.1 $ (3,001 )
Cost of goods sold for the Treatment Segment decreased by approximately $120,000 or 0.9%. Treatment Segment’s variable costs decreased by approximately $289,000 primarily in disposal, transportation, material and supplies and outside services due to lower revenue. Treatment Segment’s overall fixed costs were higher by approximately $169,000 resulting from the following: general expenses were higher by $171,000 in various categories; depreciation expenses were higher by approximately $80,000 due to more financed leases; regulatory expenses were higher by approximately $23,000; maintenance expenses were lower by $89,000; and travel expenses were lower by $16,000 due to restrictions implemented from the impact of COVID-19. Services Segment cost of goods sold decreased $2,881,000 or 11.1% primarily due to lower revenue. The decrease in cost of goods sold was primarily due to lower salaries/payroll related, travel, and outside services expenses totaling approximately $2,082,000 with the remaining lower costs in material and supplies, disposal, regulatory, and general expenses. Included within cost of goods sold is depreciation and amortization expense of $787,000 and $699,000 for the six months ended June 30, 2021, and 2020, respectively.
28
Gross Profit
~~Gross Profit (Negative Gross Profit)~~
Gross profit for the quarter ended ~~June 30, 2021~~March 31, 2022 decreased ~~$2,344,000~~$720,000 over the ~~same~~corresponding period ~~in 2020,~~of 2021, as follows:

% % % %
(In thousands) 2021 Revenue 2020 Revenue Change 2022 Revenue 2021 Revenue Change
Treatment $ 1,433 18.6 $ 1,695 21.6 $ (262 ) $ 638 8.5 $ 925 12.3 $ (287 )
Services (467 ) (5.5 ) 1,615 11.4 (2,082 ) 998 11.8 1,431 9.2 (433 )
Total $ 966 6.0 $ 3,310 15.0 $ (2,344 ) $ 1,636 10.3 $ 2,356 10.2 $ (720 )

Treatment Segment gross profit decreased by ~~$262,000~~$287,000 or 31.0% and gross margin decreased to ~~18.6%~~8.5% from ~~21.6%~~12.3% primarily due to ~~lower revenue from lower waste volume and~~ the impact of our fixed costs. Services Segment gross profit decreased by ~~$2,082,000~~$433,000 or ~~128.9%~~30.3% and gross margin ~~decreased~~increased from ~~11.4%~~9.2% to a negative 5.5% primarily due to lower revenue. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.
~~Gross profit for the six months ended June 30, 2021 decreased $4,628,000 over 2020, as follows:~~
% %
(In thousands) 2021 Revenue 2020 Revenue Change
Treatment $ 2,358 15.5 $ 4,440 25.5 $ (2,082 )
Services 964 4.0 3,510 11.9 (2,546 )
Total $ 3,322 8.5 $ 7,950 16.9 $ (4,628 )
Treatment Segment gross profit decreased by $2,082,000 and gross margin decreased to 15.5% from 25.5% primarily due to lower revenue from lower waste volume and the impact of our fixed costs. Services Segment gross profit decreased by $2,546,000 or 72.5% and gross margin decreased from 11.9% to 4.0% primarily due to lower revenue.11.8%. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.

SG&A

SG&A expenses increased ~~$297,000~~$217,000 for the three months ended ~~June 30, 2021,~~March 31, 2022, as compared to the corresponding period for ~~2020,~~2021, as follows:

(In thousands) 2021
%
Revenue
2020
%
Revenue
Change 2022 % Revenue 2021 % Revenue Change
Administrative $ 1,291 — $ 1,296 — $ (5 ) $ 1,687 — $ 1,372 — $ 315
Treatment 901 11.7 867 11.1 34 1,040 13.9 978 13.0 62
Services 805 9.5 537 3.8 268 695 8.2 855 5.5 (160 )
Total $ 2,997 18.6 $ 2,700 12.2 $ 297 $ 3,422 21.5 $ 3,205 13.9 $ 217
26

~~The overall increase in SG&A was primarily within our Services Segment where~~Administrative SG&A expenses ~~increased~~were higher primarily due to the following: outside services expenses were higher by approximately ~~$268,000.~~$174,000 resulting from more consulting/legal/outside services matters; salaries and payroll related expenses were higher by approximately $116,000 primarily due to higher stock-based compensation expenses from options granted to certain employees in October 2021 and higher salaries as in 2021, resources were allocated in supporting Medical Segment’s R&D/administrative functions; director fees were higher by approximately $18,000 resulting from one additional director who joined the Board in May 2021; travel expenses were higher by approximately $12,000; and general expenses were lower by approximately $5,000. Treatment Segment SG&A expenses were higher primarily due to higher trade show and travel costs resulting from easing up of COVID-19 restrictions. The ~~increase~~decrease in SG&A expenses within our Services Segment was primarily due to the following: ~~salaries and~~ salaries/payroll related and consulting expenses were ~~higher~~lower by approximately ~~$185,000 primarily due to~~$130,000 as in 2021, increased hours and consulting costs were spent ~~for~~on bid and ~~proposals~~proposal efforts; bad debt expenses were lower by approximately $38,000; general expenses were slightly lower by $6,000 and ~~higher healthcare costs;~~ travel expenses were higher by approximately $12,000 due to ease of travel restrictions since the start of the pandemic; outside services expenses were higher by approximately $92,000 primarily due to more consulting matters related to bid and proposals; and general expenses were lower by approximately $21,000. Administrative SG&A expenses were slightly lower primarily due to the following: payroll related expenses were lower by approximately $98,000 primarily due to forfeiture of 401(k) plan matching funds contributed by us for former employees who failed to meet the 401(k) plan vesting requirements; director fees were higher by approximately $60,000 resulting from one additional director and fee increases that went into effect January 1, 2021; travel expenses were higher by approximately $13,000 due to ease of travel restrictions since the pandemic; outside services expenses were higher by approximately $14,000 resulting from more consulting/subcontract/legal matters; and general expenses were slightly higher by approximately $6,000. Treatment Segment SG&A expenses were higher due to the following: bad debt expenses were higher by approximately $69,000 as in the second quarter of 2020, certain customer accounts which had previously been reserved for were collected; travel expenses were slightly higher by approximately $5,000 due to ease of travel restrictions since the start of the pandemic; general expenses were slightly higher by approximately $10,000; and salaries and payroll related expenses were lower by approximately $50,000.$14,000. Included in SG&A expenses is depreciation and amortization expense of ~~$6,000~~$17,000 and $6,000 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively.~~
29
~~SG&~~A ~~expenses increased $575,000 for the six months ended June 30, 2021, as compared to the corresponding period for 2020, as follows:~~
(In thousands) 2021 % Revenue 2020 % Revenue Change
Administrative $ 2,662 — $ 2,655 — $ 7
Treatment 1,880 12.4 1,928 11.1 (48 )
Services 1,660 6.9 1,044 3.5 616
Total $ 6,202 15.8 $ 5,627 12.0 $ 575
The overall increase in SG&A was primarily within our Services Segment where SG&A expenses increased by approximately $616,000. The increase in SG&A expenses within our Services Segment was primarily due to the following: salaries and payroll related expenses were higher by approximately $371,000 primarily due to increased hours spent for bid and proposals; outside services expenses were higher by approximately $192,000 due to more consulting matters related to bid and proposals; bad debt expenses were higher by approximately $40,000 as in the first quarter of 2020, certain customer accounts which had previously been reserved for were collected; and general expenses were slightly higher by $13,000. Administrative SG&A expenses were slightly higher primarily due to the following: director fees were higher by approximately $119,000 resulting from one additional director and fee increases that went into effect January 1, 2021; general expenses were slightly higher by approximately $5,000; payroll related expenses were lower by approximately $79,000 primarily due to forfeiture of 401(k) plan matching funds contributed by us for former employees which failed to meet the 401(k) plan vesting requirements; travel expenses were lower by approximately $10,000 due to less travel due to COVID-19; and outside services expenses were lower by approximately $28,000 resulting from fewer consulting/subcontract/legal matters. Treatment Segment SG&A expenses were lower due to the following: travel expenses were lower by approximately $44,000 due to less travel resulting from COVID-19; general expenses were lower by $101,000 in various categories; bad debt expenses were higher by approximately $50,000 as in the second quarter of 2020, certain customer accounts which had previously been reserved for were collected; salaries and payroll related expenses were higher by approximately $36,000 due to increased hours spent on bid and proposals and higher healthcare costs; and outside services expenses were higher by approximately $11,000 primarily due to more consulting matters. Included in SG&A expenses is depreciation and amortization expense of $12,000 and $12,000 for the six months ended June 30, 2021 and 2020, respectively.

R&D
R&D expenses decreased ~~$65,000 and $146,000~~$54,000 for the three ~~and six~~ months ended ~~June 30, 2021, respectively,~~March 31, 2022, as compared to the corresponding period ~~of 2020.~~for 2021, as follows:

Three Months Ended June 30, Six Months Ended June 30,
(In thousands) 2021 2020 Change 2021 2020 Change 2022 2021 Change
Administrative $ 10 $ 37 $ (27 ) $ 24 $ 44 $ (20 ) $ 17 $ 14 $ 3
Treatment 43 52 (9 ) 90 145 (55 ) 65 47 18
Services 19 46 (27 ) 32 112 (80 ) 14 13 1
PF Medical 72 74 (2 ) 149 140 9 — 76 (76 )
Total $ 144 $ 209 $ (65 ) $ 295 $ 441 $ (146 ) $ 96 $ 150 $ (54 )
30

R&D costs consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of new technologies and technological enhancement of new potential waste treatment processes. The decrease was primarily the result of the sale of PF Poland in December 2021 which comprised of our Medical Segment and which previously was involved in the R&D of our medical isotope technology.

~~Interest Income~~
Interest income decreased by approximately $26,000 and $63,000 for the three and six months ended June 30, 2021, respectively, as compared to the corresponding period of 2020 primarily due to lower interest earned from lower finite risk sinking fund.
Interest Expense

Interest expense decreased by approximately ~~$34,000 and $87,000 for~~$32,000 in the ~~three and six months ended June 30, 2021, respectively,~~first quarter of 2022 as compared to the corresponding period of ~~2020~~2021 primarily due to lower interest expense from our declining term loan balance ~~outstanding and lower interest rate.~~outstanding. Also, interest expense for the first quarter of 2021 included interest accrued for our Paycheck Protection Program (“PPP”) Loan which was ~~lower resulting from~~forgiven by the ~~payoff of the $2,500,000 loan at year end 2020 that we had previously entered into with Robert Ferguson on April 1, 2019.~~U.S. Small Business Administration effective June 15, 2021.

~~Interest Expense- Financing Fees~~Income Taxes
We had income tax benefit of approximately $673,000 for continuing operations for the three months ended March 31, 2022 as compared to income tax benefit of approximately $17,000 for continuing operations for the three months ended March 31, 2021. Our effective tax rate was approximately 35.0% and 1.6% for the three months ended March 31, 2022 and the corresponding period of 2021, respectively. Our tax rate for the three months ended March 31, 2022 was impacted by non-deductible expenses and state taxes. Our tax rate for the three months ended March 31, 2021 was impacted by non-deductible expenses, state taxes, and the full valuation on our net deferred tax assets which was subsequently released partially in the third quarter of 2021.

27
Interest expense-financing fees decreased by approximately $51,000 and $112,000 for the three and six months ended June 30, 2021, respectively, as compared to the corresponding period 2020 primarily due to debt discount/debt issuance costs that became fully amortized as financing fees at year end 2020 in connection with the issuance of our Common Stock and a purchase Warrant as consideration for us receiving the $2,500,000 loan from Robert Ferguson dated April 1, 2019.

Liquidity and Capital Resources
Our cash flow requirements during the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 were primarily financed by our operations, cash on hand and credit facility availability. Subject to the impact of COVID-19 and other delays as discussed above, our cash flow requirements for the next twelve months will consist primarily of general working capital needs, scheduled principal payments on our debt obligations, remediation projects, and planned capital expenditures. We plan to fund these requirements from our operations, credit facility availability, our capital expenditure line and cash on ~~hand~~hand. We continue to explore all sources of increasing our capital to supplement our liquidity requirements, when needed, and ~~if deemed appropriate, other sources available~~ to ~~us.~~improve our revenue and working capital. We are continually reviewing operating costs and reviewing the possibility of further reducing operating costs and non-essential expenditures to bring them in line with revenue levels, when necessary. At this time, we believe that our cash flows from operations, our available liquidity from our credit facility, our capital expenditure line and our cash on hand should be sufficient to fund our operations for the next twelve months. However, due to the uncertainty of COVID-19 ~~continued~~and other delays as disclosed in ~~waste shipments from certain customers, delays in procurement actions~~“COVID-19 Impact and contract awards, and/or certain reserves that our lender has placed (see the amendment that we entered into with our lender in August 2021 in “Financing Activities” below) or may place in the future against our revolving line of credit,Impact due to Other Delays” within this MD&A, there are no assurances such will be the case.As a result, we continue to explore all sources, including, but not limited to, selling additional stock of ours under our currently effective shelf registration, to increase our capital or supplement our liquidity requirements and working capital. As previously disclosed, our Medical Segment, which has not generated any revenues, has substantially reduced its R&D costs and activities due to the need for capital to fund such activities. We continue to seek various sources of potential funding for our Medical Segment. We anticipate that our Medical Segment will not resume full R&D activities until it obtains the necessary funding through obtaining its own credit facility or additional equity raise or obtaining new partners willing to fund its R&D activities. If the Medical Segment is unable to raise the necessary capital, the Medical Segment could be required to further reduce, delay or eliminate its R&D program.
31

The following table reflects the cash flow activities during the first ~~six~~three months of ~~2021:~~2022:

(In thousands)
Cash provided by operating activities of continuing operations $ 803 $ 148
Cash used in operating activities of discontinued operations (315 ) (142 )
Cash used in investing activities of continuing operations (649 ) (321 )
Cash used in financing activities of continuing operations (439 ) (189 )
Effect of exchange rate changes in cash 9
Decrease in cash and finite risk sinking fund (restricted cash) $ (591 ) $ (504 )

At ~~June 30, 2021,~~March 31, 2022, we were in a positive cash position with no revolving credit balance. At ~~June 30, 2021,~~March 31, 2022, we had cash on hand of approximately ~~$7,312,000,~~$3,925,000, which ~~includes~~included account balances of our foreign subsidiaries totaling approximately ~~$675,000.~~$67,000.

Operating Activities
Accounts receivable, net of allowances for doubtful accounts, totaled ~~$9,244,000~~$10,322,000 at ~~June 30, 2021,~~March 31, 2022, a decrease of ~~$415,000~~$1,050,000 from the December 31, ~~2020~~2021 balance of ~~$9,659,000.~~$11,372,000. The decrease was primarily due to timing of accounts receivable collection and timing of invoicing. Our contracts with our customers are subject to various payment terms and conditions; therefore, our accounts receivable are impacted by these terms and conditions and the related timing of accounts receivable collections. Additionally, contracts with our customers may sometimes result in modifications which can cause delays in collections. See discussion under “Known Trends and Uncertainties – Perma-Fix Canada, Inc. (“PF Canada”) for a discussion as to certain account receivable.

Unbilled receivables totaled ~~$7,332,000~~$5,275,000 at ~~June 30, 2021,~~March 31, 2022, a decrease of ~~$7,121,000~~$3,720,000 from the December 31, ~~2020~~2021 balance of ~~$14,453,000.~~$8,995,000. The decrease in unbilled receivables was primarily within our Services Segment due to invoicing ~~and collection of accounts receivable on certain large projects which have been completed or are near completion.~~in connection with our Canadian projects.

Accounts payable, totaled ~~$11,511,000~~$10,329,000 at ~~June 30, 2021,~~March 31, 2022, a decrease of ~~$3,871,000~~$1,646,000 from the December 31, ~~2020~~2021 balance of ~~$15,382,000.~~$11,975,000. Our accounts payable are impacted by the timing of payments as we are continually managing payment terms with our vendors to maximize our cash position throughout all segments.

We had working capital of ~~$3,394,000~~$2,341,000 (which included working capital of our discontinued operations) at ~~June 30, 2021,~~March 31, 2022, as compared to working capital of ~~$3,672,000~~$4,060,000 at December 31, ~~2020.~~2021. Our working capital was ~~primarily~~ negatively impacted primarily by ~~lower revenue generated within both~~our results of ~~our segments in the first six months of 2021. However, this negative impact to our working capital was positively~~operations which were heavily impacted ~~by the forgiveness of the entire balance of our PPP Loan, along with accrued interest, by the SBA effective June 15, 2021 (see “CARES Act – PPP Loan” for information on this loan”).~~from COVID-19 and other delays as discussed above.
28

Investing Activities
For the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, our purchases of capital equipment totaled approximately ~~$679,000,~~$459,000, of which ~~$29,000~~$114,000 was subject to financing, with the remaining funded from cash from operations and our credit facility. We have budgeted approximately $2,000,000 for ~~2021~~2022 capital expenditures primarily for our Treatment and Services Segments to maintain operations and regulatory compliance requirements and support revenue growth. Certain of these budgeted projects may either be delayed until later years or deferred altogether. We plan to fund our capital expenditures from cash from operations and/or financing. The initiation and timing of projects are also determined by financing alternatives or funds available for such capital projects.

During March 2022, we signed a joint venture term sheet addressing plans to partner with Springfields Fuels Limited (“SFL”), an affiliate of Westinghouse Electric Company LLC, to develop and manage a nuclear waste-materials treatment facility (the “Facility”) in the United Kingdom. The Facility is for the purpose of expanding the partners’ waste treatment capabilities for the European nuclear market. It is expected that upon finalization of a partnership agreement, SFL will have an ownership interest of fifty-five (55) percent and our interest will be forty-five (45) percent. The finalization, form and capitalization of this unpopulated partnership is subject to numerous conditions, including but not limited to, winning a certain contract, completion and execution of a definitive agreement and facility design, and the granting of required regulatory, lender or permitting approvals. Upon finalization of this venture, we will be required to make an investment in this venture. The amount of our investment, the period of which it is to be made and the method of funding are to be determined.
Financing Activities

We entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020 (“Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The Loan Agreement provides us with the following credit facility with a maturity date of March 15, 2024: (a) up to $18,000,000 revolving credit (“revolving credit”) and (b) a term loan (“term loan”) of approximately $1,742,000, requiring monthly installments of $35,547. The maximum that we can borrow under the revolving credit is based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that our lender may impose from time to time. Our Loan Agreement, as amended, also provides a capital expenditure line of up to $1,000,000 with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during the Borrowing Period. At the end of the Borrowing Period, the total amount advanced under the line will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, as amended, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of March 31, 2022.
32

On ~~May 4, 2021,~~March 29, 2022, we entered into an amendment to our Loan Agreement with our lender which provided, ~~the following,~~ among other ~~things:~~things, the following:

● ~~revised~~waived our ~~fixed charge coverage ratio (“FCCR”) calculation~~failure to meet the minimum quarterly FCCR requirement ~~which allows~~ for the ~~add-back~~fourth quarter of ~~approximately $5,318,000 in eligible expenses that were incurred~~2021;
● removes the quarterly FCCR testing requirement for the first quarter of 2022;
● reinstates the quarterly FCCR testing requirement starting for the second quarter of 2022 and ~~covered by~~revises the ~~PPP Loan that we received in 2020. The add-back is~~methodology to be ~~applied retroactively~~used in calculating the FCCR for the quarters ending June 30, 2022, September 30, 2022, and December 31, 2022 (with no change to the ~~second~~minimum 1.15:1 ratio requirement for each quarter);
● requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and ~~third quarters of 2020. (see below for a discussion of~~certified to the ~~PPP Loan);~~lender; and
● arevises the annual rate used to calculate the Facility Fee (as defined in the Loan Agreement) on the revolving credit, with addition of the capital expenditure line, from 0.375% to 0.500%. Upon meeting the minimum FCCR requirement of ~~up to $1,000,000 with advances~~1.15:1 on ~~the line, subject to certain limitations, permitted for up to~~a twelve months ~~starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during~~trailing basis, the ~~Borrowing Period (see annual~~Facility Fee rate of ~~interest below on the capital expenditure line). At the end of the Borrowing Period, the total amount advanced under the line~~0.375% will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of June 30, 2021.be reinstated.

In connection with the amendment, we paid our lender a fee of ~~$15,000.~~$15,000 which is being amortized over the remaining term of the Loan Agreement, as amended, as interest expense-financing fees.
29

Pursuant to our Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit is at prime ~~(3.25%~~(3.50% at ~~June 30, 2021)~~March 31, 2022) plus 2% or ~~London InterBank Offer Rate (“LIBOR”)~~LIBOR plus 3.00% and the term loan and capital expenditure line at prime plus 2.50% or LIBOR plus 3.50%. Under the LIBOR option of interest payment, a LIBOR floor of 0.75% applies in the event that LIBOR falls below 0.75% at any point in time.
~~On August 10, 2021, we entered into an amendment to our Loan Agreement with our lender which provided, among other things, the following:~~
● ~~waived our failure to meet the minimum quarterly FCCR requirement for the second quarter of 2021;~~
● ~~removes the quarterly FCCR testing requirement for the third quarter of 2021;~~
● reinstates the quarterly FCCR testing requirement starting for the fourth quarter of 2021 and revises the methodology to be used in calculating the FCCR for the quarters ending December 31, 2021, March 31, 2022, and June 30, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter); ~~and~~
● requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended December 31, 2021 has been met and certified to the lender.
~~In connection with the amendment, we paid our lender a fee of $15,000.~~
We may terminate our Loan Agreement upon 90 days’ prior written notice upon payment in full of our obligations under the Loan Agreement. We agreed to pay PNC 1.0% of the total financing had we paid off our obligations on or before May 7, 2021 and 0.5% of the total financing if we pay off our obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee will apply if we pay off our obligations under the Loan Agreement after May 7, 2022.
33
At June 30, 2021, the borrowing availability under our revolving credit was approximately $9,550,000, based on our eligible receivables and includes a reduction in borrowing availability of approximately $3,020,000 from outstanding standby letters of credit.

Our credit facility under our Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. We ~~met our financial covenant requirements~~were not required to perform testing of the FCCR requirement in the first quarter of ~~2021. Our FCCR calculation in~~2022 pursuant to the ~~first quarter of 2021 included the add-back of approximately $5,318,000 in eligible expenses that were incurred and covered by the PPP Loan that we received in 2020 as permitted by the~~March 29, 2022 amendment ~~dated May 4, 2021~~ as discussed ~~above. We did not meet~~above; otherwise, we met all of our ~~FCCR requirement in the second quarter of 2021; however, this non-compliance was waived by our lender as discussed above.~~other financial covenant requirements. We expect to meet our quarterly financial covenant requirements for the next twelve months under our Loan ~~Agreement, as amended, as discussed above.~~Agreement.

~~The CARES Act~~
~~PPP Loan~~
On April 14, 2020, we entered into a promissory note under the PPP with PNC, our credit facility lender, which had a balance of approximately $5,318,000 (the “PPP Loan”) at March 31, 2021. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and is administered by the SBA. The CARES Act was subsequently amended by the Paycheck Protection Program Flexibility Act of 2020 (“Flexibility Act”). Proceeds from the promissory note was used by us for eligible payroll costs, mortgage interest, rent and utility costs as permitted under the Flexibility Act. The annual interest rate on the PPP Loan is 1.0%
On October 5, 2020, we applied for forgiveness on repayment of the PPP Loan as permitted under the Flexibility Act. On July 1, 2021, we were notified by PNC that the entire balance of the PPP Loan of approximately $5,318,000, along with accrued interest of approximately $63,000 was forgiven by the SBA, effective June 15, 2021. Accordingly, we recorded the entire forgiven PPP Loan balance, along with accrued interest, totaling approximately $5,381,000 as “Gain on extinguishment of debt” on our Consolidated Statement of Operations for the quarter ended June 30, 2021.
~~Deferral of Employment Tax Deposits~~
The Flexibility Act provides employers the option to defer the payment of an employer’s share of social security taxes beginning on March 27, 2020 through December 31, 2020, with 50% of the amount of social security taxes deferred to become due on December 31, 2021 with the remaining 50% due on December 31, 2022. We elected to defer such taxes starting in mid-April 2020. At June 30, 2021, we have deferred payment of approximately $1,252,000 in our share of social security taxes, of which approximately $626,000 is included in “Other long-term liabilities,” with the remaining balance included in “Accrued expenses” within current liabilities in the Company’s Consolidated Balance Sheets.
Off Balance Sheet Arrangements
From time to time, we are required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At ~~June 30, 2021,~~March 31, 2022, the total amount of standby letters of credit outstanding totaled approximately $3,020,000 and the total amount of bonds outstanding totaled approximately ~~$43,561,000.~~$51,295,000. We also provide closure and post-closure requirements through a financial assurance policy for certain of our Treatment Segment facilities through AIG. At ~~June 30, 2021,~~March 31, 2022, the closure and post-closure requirements for these facilities were approximately ~~$19,898,000.~~$21,047,000.

Critical Accounting Policies and Estimates
There were no significant changes in our accounting policies or critical accounting estimates that are discussed in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

34
Recent Accounting Pronouncements

See “Note 2 – Summary of Significant Accounting Policies” in the “Notes to Consolidated Financial Statements” for the recent accounting pronouncements that have been adopted during the ~~first six months of 2021,~~quarter ended March 31, 2022, or will be adopted in future periods.

Known Trends and Uncertainties

Significant Customers. Our Treatment and Services Segments have significant relationships with the U.S ~~and Canadian~~ governmental authorities through contracts entered into indirectly as subcontractors for others who are prime contractors or directly as the prime contractor to government authorities. ~~As stated previously, our governmental~~We also had significant relationships with Canadian government authorities primarily through TOAs entered into with Canadian government authorities. Project work under all TOAs with Canadian government authorities has substantially been completed. The contracts ~~and subcontracts relating~~that we are a party to ~~activities~~with others as subcontractors to the U.S federal government or directly with the U.S federal government generally provide that the government may terminate the contract at ~~governmental sites in the United States are generally subject to termination or renegotiation on 30 days’ notice~~any time for convenience at the government’s ~~option, and our~~option. The contracts/TOAs that we are a party to with Canadian governmental ~~contracts/task orders with~~authorities also generally provide that the ~~Canadian~~ government authorities ~~allow the authorities to~~may terminate the ~~contract/task orders~~contracts/TOAs at any time for any reason for convenience. Our inability to continue under existing ~~material~~ contracts that we have with the U.S government ~~and Canadian government authorities~~ (directly or indirectly as a subcontractor) or significant reductions in the level of governmental funding in any given year could have a material adverse impact on our operations and financial condition.
We performed services relating to waste generated by government clients (domestic and foreign (primarily Canadian)), either indirectly as a subcontractor or directly as a prime contractor ~~or indirectly for others as a subcontractor~~ to government entities, representing approximately ~~$13,671,000~~$14,158,000 or ~~84.7% and $33,828,000 or 86.1%~~89.0% of our total ~~revenues generated~~revenue during the three ~~and six~~ months ended ~~June 30, 2021, respectively,~~March 31, 2022, as compared to ~~$19,811,000~~$20,157,000 or ~~89.9% and $42,313,000 or 90.2%~~87.1% of our total ~~revenues generated~~revenue during the ~~three~~corresponding period of 2021.
COVID-19 Impact. See “COVID-19 Impact and ~~six months ended June 30, 2020.~~Impact due to Other Delays” within this MD&A for a discussion of the impact of COVID-19 on our financial results and the potential impact it may have to our future financial results and business operations.
30
Perma-Fix Canada, Inc. (“PF Canada”)
During the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from CNL on a TOA that PF Canada entered into with CNL in May 2019 for remediation work within Ontario, Canada (“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has since been completed. CNL may terminate the TOA at any time for convenience. As of March 31, 2022, PF Canada has approximately $2,722,000 in unpaid receivables and unbilled costs due from CNL as a result of work performed under the TOA. Additionally, CNL has approximately $1,150,000 in contractual holdback under the TOA that is payable to PF Canada. CNL also established a bond securing approximately $1,900,000 (CAD) to cover certain issue raised in connection with the TOA. Under the TOA, CNL may be entitled to set off certain costs and expenses incurred by CNL in connection with the termination of the TOA, including the bond as discussed above, against amounts owed to PF Canada for work performed by PF Canada or its subcontractors. PF Canada continues to be in discussions with CNL to finalize the amounts due to PF Canada under the TOA and continues to believes these amounts are due and payable.

~~COVID-19 Impact.~~Supply Chain. ~~The extent~~We use various commercially available materials and supplies which include among other things chemicals, containers/drums and personal protective equipment in our operations. We generally source these items from various suppliers in order to take advantage of ~~the impact~~competitive pricing.
We also utilize various types of ~~the COVID-19 pandemic on~~equipment, which include among other things trucks, flatbeds, lab equipment, heavy machineries, in carrying out our business ~~continues to~~operations. Our equipment may be uncertain and difficult to predict, as the responses to the pandemic continue to evolve rapidly. We continue to experience delays in waste shipments from certain customers within our Treatment Segment primarily related to the impact of COVID-19. However, we expect to see returns in waste receipts from these customers in the second half of 2021.obtained through direct purchase, rental option or leases. Within our Services Segment, equipment required for projects are often provided by our subcontractors as part of our contract agreement with the subcontractor. Due to some of our specialized waste treatment processes, certain equipment that we ~~continue~~utilize are designed and built to ~~experience~~our specifications. We rely on various commercial equipment suppliers for the construction of these equipment. Due to recent supply chain challenges, we experienced a delay in the delivery of a new waste processing unit to us by our supplier due to shortage of parts required for the construction of the unit, among other things. Delivery of this unit was expected during the third quarter of 2021 but did not occur until the latter part of the first quarter of 2022. The supply chain interruption delayed deployment of our new technology which negatively impacted our revenue for 2021 and the first quarter of 2022 as associated revenue was not able to be generated. Deployment of this unit is expected to commence in the second quarter of 2022. Continued increases in pricing and/or potential delays in ~~procurement actions~~procurements of material and ~~contract awards~~supplies and equipment required for our operations resulting ~~primarily~~ from ~~the impact of COVID-19 but have recently begun to receive contract awards. We expect procurement actions~~further tightening supply chain could further adversely affect our operations and ~~contract awards to continue throughout the second half of 2021. Within our Treatment and Services Segments, we have an unprecedented number of bids currently submitted and awaiting awards.~~profitability.

~~The severity~~Potential Partnership with Springfields Fuels Limited. As discussed above, we have signed a term sheet addressing plans to partner with Springfields Fuels Limited, an affiliate of Westinghouse Electric Company LLC, to develop and manage a nuclear waste-materials treatment facility in the ~~impact the COVID-19 pandemic on our business will depend on~~United Kingdom. See “Liquidity and Capital Resources – Investing Activities” of this MD&A for a ~~number~~discussion of ~~factors, including, but not limited to, the duration~~this transaction.
Inflation and severity of the pandemic, impact from the emergence of new variants of the virus, the extent and severity of the impact on our customers, the impact on governmental programs and budgets, inoculation rate of the vaccines, and how quickly and to what extent normal economic and operating conditions resume, all of which are uncertain and cannot be predicted with any accuracy or confidence at this time. Our future results of operations and liquidity could be adversely impacted from continued delaysCost Increases. Continued increases in ~~waste shipments, continued delays in procurement actions and contract awards, and/or recurrence of project work shut downs as well as potential partial/full shutdown of~~ any of our ~~facilities due~~operating costs, including further changes in fuel prices (which impacts our transportation costs), wage rates, supplies, and utility costs, may further increase our overall cost of goods sold or operating expenses. Some of these cost increases have been the result of inflationary pressures that could further reduce profitability. We may attempt to ~~COVID-19.~~increase our sales prices in order to maintain satisfactory margin; however, competitive pressures in our industry may have the effect of inhibiting our ability to reflect these increased costs in the prices of our services that we provide to our customers and therefore reduce our profitability.

Environmental Contingencies

We are engaged in the waste management services segment of the pollution control industry. As a participant in the on-site treatment, storage and disposal market and the off-site treatment and services market, we are subject to rigorous federal, state and local regulations. These regulations mandate strict compliance and therefore are a cost and concern to us. Because of their integral role in providing quality environmental services, we make every reasonable attempt to maintain complete compliance with these regulations; however, even with a diligent commitment, we, along with many of our competitors, may be required to pay fines for violations or investigate and potentially remediate our waste management facilities.

3531

We routinely use third party disposal companies, who ultimately destroy or secure landfill residual materials generated at our facilities or at a client’s site. In the past, numerous ~~third party~~third-party disposal sites have improperly managed waste and consequently require remedial action; consequently, any party utilizing these sites may be liable for some or all of the remedial costs. Despite our aggressive compliance and auditing procedures for disposal of wastes, we could further be notified, in the future, that we are a potentially responsible party (“PRP”) at a remedial action site, which could have a material adverse effect.

~~Our subsidiaries where~~We have three environmental remediation ~~expenditures will be made are at three sites~~projects, all within our discontinued ~~operations. While no assurances can be made that we will be able to do so, we~~operations, which principally entail the removal/remediation of contaminated soil, and, in most cases, the remediation of surrounding ground water. We expect to fund the expenses to remediate these sites from funds generated from operations.
At ~~June 30, 2021,~~March 31, 2022, we had total accrued environmental remediation liabilities of ~~$781,000, a decrease of $73,000~~$876,000, with no change from the December 31, ~~2020~~2021 balance of ~~$854,000. The decrease represents primarily payments made on remediation projects.~~$876,000. At ~~June 30, 2021, $671,000~~March 31, 2022, $621,000 of the total accrued environmental liabilities was recorded as current.

~~Item 3. Quantitative and Qualitative Disclosures about Market Risks~~
Item 3. Quantitative and Qualitative Disclosures about Market Risks
Not required for smaller reporting companies.

Item 4.
~~Item 4.~~ Controls and Procedures
~~(a)~~ ~~Evaluation of disclosure controls and procedures.~~

(a)
Evaluation of disclosure controls, and procedures.
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management. As of the end of the period covered by this report, we carried out an evaluation with the participation of our Principal Executive Officer and Principal Financial Officer. Based on this recent assessment, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) were not effective as of ~~June 30,~~March 31, 2022 as a result of the identified material weakness in our internal control over financial reporting as set forth below.
Certain revenue contracts that contained nonstandard terms and conditions were not appropriately evaluated in accordance with ASC 606, “Revenue from Contracts with Customers.” Specifically, management did not have the appropriate controls in place over the determination of revenue recognition for nonroutine and complex revenue transactions. The material weakness identified resulted in errors in the Company’s books and records which led to audit adjustments for the year ended December 31, 2021. The errors arising from the underlying revenue adjustments were not material to the financial statements reported in any interim or annual period and therefore, did not result in a revision to any previously filed financial statements. However, the control deficiencies could result in misstatements of the revenue accounts and related disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected in a timely manner. Accordingly, we have determined that the control deficiencies when evaluated in the aggregate constitute a material weakness.
32
Remediation of Material Weakness in Internal Control Over Financial Reporting
The material weakness as discussed above was primarily attributed to the uniqueness of certain of the Company’s contracts that contain nonstandard terms and conditions. Although the Company’s policies and procedures were in place to ensure guidance under ASC 606 were applied to the majority of its contracts accurately, the Control failed to operate in a manner to specifically identify the nonstandard terms that would impact revenue recognition. The Company is evaluating the material weakness identified and is developing a plan of remediation to strengthen our internal controls pertaining to evaluating revenue contracts that contain nonstandard terms and conditions. This remediation plan includes evaluating the manner in which we use third-party consulting firms with expertise in applying the revenue recognition guidance that will assist management with the assessment and evaluation of revenue contracts executed that contain nonstandard terms and conditions. In conjunction with further evaluation of this relationship, management will also perform a more rigorous evaluation of these nonstandard revenue contracts in accordance with ASC 606.
The Company is committed to maintaining a strong internal control environment and believes that these remediation efforts will represent significant improvements in our controls. The Company has started to implement these steps, however, some of these steps will take time to be fully integrated and confirmed to be effective and sustainable. Additional controls may also be required over time. Until the remediation steps set forth above are fully implemented and tested, the material weakness described above will continue to exist.

(b) Changes in internal control over financial ~~reporting.~~reporting
~~There~~Other than the aforementioned material weakness and remediation plan noted, there was no other change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
36
PART II – OTHER INFORMATION

~~Item 1.~~ ~~Legal Proceedings~~
Item 1. Legal Proceedings

There are no material legal proceedings pending against us and/or our subsidiaries not previously reported by us in Item 3 of our Form 10-K for the year ended December 31, ~~2020.~~2021. Additionally, there has been no other material change in legal proceedings previously disclosed by us in our Form 10-K for the year ended December 31, ~~2020.~~2021.

~~Item 1A. Risk Factors~~
Item 1A. Risk Factors

There has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31, ~~2020.~~2021, except for the following under “Risks Relating to our Common Stock.”
Our bylaws designate courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, and also designates the Federal District Courts of the United States as the sole and exclusive forum for resolution of any cause of action arising under the Securities Act of 1933, as amended, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our Bylaws provide that, subject to limited exceptions, the appropriate state court located in the State of Delaware (or if no state court located within the State of Delaware has jurisdiction, the Federal District Court for the District of Delaware) is the sole and exclusive forum for:

~~Item 6.~~ ~~Exhibits~~ ● any derivative action or proceeding brought on our behalf;
~~(a)~~ ~~Exhibits~~

● ~~4.1~~any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders;
33
Second Amended and Restated Revolving Credit, Term Loan and Security Agreement between Perma-Fix Environmental Services, Inc. and PNC Bank, National Association (as Lender and as Agent), dated May 8, 2020, as incorporated by reference from Exhibit 4.1● any action asserting a claim against us arising pursuant to any provision of the ~~Company’s Form 10-Q for~~General Corporation Law of the ~~quarter ended March 31, 2020 filed on May 12, 2020.~~State of Delaware, our certificate of incorporation or our bylaws:
~~4.2~~
● any action asserting an “internal corporation claim” (as defined in Section 115 of the Delaware General Corporate Law); or
● any other action asserting a claim against us that is governed by the internal affairs doctrine (each, a “Covered Proceeding”).
In addition, our Bylaws provide that if any action the subject matter of which is a Covered Proceeding is filed in a court other than the specified Delaware courts without the approval of our Board of Directors (each, a “Foreign Action”), the claiming party will be deemed to have consented to (i) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (ii) having service of process made upon such claiming party in any such enforcement action by service upon such claiming party’s counsel in the Foreign Action as agent for such claiming party.
Further, our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Federal District Courts of the United States shall be the sole and exclusive forum for the resolution of any complaint asserting a course of action under the Federal Securities Act of 1933, as amended.
These provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our Bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.
Item 6. Exhibits
(a) Exhibits
4.1 ~~First~~Third Amendment to Second Amended and Restated Revolving Credit, Term Loan and Security Agreement between Perma-Fix Environmental Services, Inc. and PNC Bank, National Association (as Lender and as Agent), dated ~~May 4, 2021,~~March 29, 2022, as incorporated by reference from Exhibit 4.1 to the Company’s Form ~~10-Q for the quarter ended March 31, 2021~~8-K filed on ~~May 6, 2021.~~April 4, 2022.
~~4.3~~10.1 ~~Second Amendment~~2022 Incentive Compensation Plan for Chief Executive Officer, effective January 1, 2022, as incorporated by reference from Exhibit 99.5 to Second Amended and Restated Revolving Credit, Term Loan and Security Agreement between Perma-Fix Environmental Services, Inc. and PNC Bank, National Association (as Lender and as Agent), dated August 10, 2021.the Company’s Form 8-K filed on January 25, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
10.2 2022 Incentive Compensation Plan for Chief Financial Officer, effective January 1, 2022, as incorporated by reference from Exhibit 99.6 to the Company’s Form 8-K filed on January 25, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
34
10.3 2022 Incentive Compensation Plan for EVP of Strategic Initiatives, effective January 1, 2022, as incorporated by reference from Exhibit 99.7 to the Company’s Form 8-K filed on January 25, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
10.4 2022 Incentive Compensation Plan for EVP of Nuclear and Technical Services, effective January 1, 2022, as incorporated by reference from Exhibit 99.8 to the Company’s Form 8-K filed on January 25, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
10.5 2022 Incentive Compensation Plan for EVP of Waste Treatment Operations, effective January 1, 2022, as incorporated by reference from Exhibit 99.9 to the Company’s Form 8-K filed on January 25, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
10.6 Joint Venture Term Sheet between Springfields Fuels Limited, an affiliate of Westinghouse, and the Company, as incorporated by reference from Exhibit 10.42 to the Company’s 2021 Form 10-K filed on April 6, 2022. CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN EXCLUDED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
31.1 Certification by Mark Duff, Chief Executive Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
31.2 Certification by Ben Naccarato, Chief Financial Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
32.1 Certification by Mark Duff, Chief Executive Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
32.2 Certification by Ben Naccarato, Chief Financial Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
101.INS Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document*Document*
101.SCH Inline XBRL Taxonomy Extension Schema Document*
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104 Cover Page Interactive Data File ~~(formatted as an~~(embedded within the Inline XBRL ~~document and included in Exhibit 101).~~document)

* Pursuant to Rule 406T of Regulation S-T, the ~~Inline~~ Interactive Data File in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

3735

SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

PERMA-FIX ENVIRONMENTAL SERVICES

Date: ~~August 11, 2021~~May 5, 2022 By: /s/ Mark Duff
Mark Duff
President and Chief (Principal) Executive Officer

Date: ~~August 11, 2021~~May 5, 2022 By: /s/ Ben Naccarato
Ben Naccarato
Chief (Principal) Financial Officer

3836

	Operating Leases			Finance Leases
2021 (Remaining)	$	211		$	353
2022		478			271
2023		486			150
2024		419			146
2025		327			146
2025 and thereafter		1,260			18
Total undiscounted lease payments		3,181			1,084
Less: Imputed interest		(787	)		(96	)
Present value of lease payments	$	2,394		$	988

			June 30, 2021							December 31, 2020
	Weighted Average Amortization		Gross					Net		Gross					Net
	Period		Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
	(Years)		Amount		Amortization			Amount		Amount		Amortization			Amount
Intangibles (amount in thousands)
Patent		12.5	$	746	$	(343	)	$	403	$	742	$	(334	)	$	408
Software		3		524		(413	)		111		418		(411	)		7
Customer relationships		10		3,370		(2,999	)		371		3,370		(2,910	)		460
Total			$	4,640	$	(3,755	)	$	885	$	4,530	$	(3,655	)	$	875

		Outside Director Stock Options Granted
		May 4, 2021
Weighted-average fair value per option	$	4.97
Risk -free interest rate ⁽¹⁾		1.61	%
Expected volatility of stock ⁽²⁾		55.91	%
Dividend yield		NaN
Expected option life ⁽³⁾		10.0 years

	Three Months Ended
	March 31,
Consolidated (amounts in thousands)	2022			%			2021			%
Revenues	$	15,915			100.0		$	23,133			100.0
Cost of good sold		14,279			89.7			20,777			89.8
Gross profit		1,636			10.3			2,356			10.2
Selling, general and administrative		3,422			21.5			3,205			13.9
Research and development		96			.6			150			.6
Loss on disposal of property and equipment		1			—			—			—
Loss from operations	$	(1,883	)		(11.8	)	$	(999	)		(4.3	)
Interest income		11			—			18			—
Interest expense		(35	)		(.2	)		(67	)		(.2	)
Interest expense-financing fees		(13	)		(.1	)		(8	)		—
Other		(2	)		—			1			—
Loss from continuing operations before taxes		(1,922	)		(12.1	)		(1,055	)		(4.5	)
Income tax benefit		(673	)		(4.3	)		(17	)		—
Loss from continuing operations	$	(1,249	)		(7.8	)	$	(1,038	)		(4.5	)

(In thousands)	2021		% Revenue		2020		% Revenue		Change			% Change			2022		% Revenue		2021		% Revenue		Change			% Change
Treatment
Government waste	$	5,102		31.6	$	5,559		25.2	$	(457	)		(8.2	)	$	5,437		34.2	$	4,387		18.9	$	1,050			23.9
Hazardous/non-hazardous ⁽¹⁾		1,317		8.1		938		4.3		379			40.4			1,001		6.3		1,311		5.7		(310	)		(23.6	)
Other nuclear waste		1,287		8.0		1,343		6.1		(56	)		(4.2	)		1,041		6.5		1,797		7.8		(756	)		(42.1	)
Total		7,706		47.7		7,840		35.6		(134	)		(1.7	)		7,479		47.0		7,495		32.4		(16	)		(0.2	)

Services
Nuclear services		8,052		49.9		13,776		62.5		(5,724	)		(41.6	)		8,281		52.0		15,080		65.2		(6,799	)		(45.1	)
Technical services		387		2.4		431		1.9		(44	)		(10.2	)		155		1.0		558		2.4		(403	)		(72.2	)
Total		8,439		52.3		14,207		64.4		(5,768	)		(40.6	)		8,436		53.0		15,638		67.6		(7,202	)		(46.1	)

Total	$	16,145		100.0	$	22,047		100.0	$	(5,902	)		(26.8	)	$	15,915		100.0	$	23,133		100.0	$	(7,218	)		(31.2	)

			%				%							%				%
(In thousands)	2021		Revenue		2020		Revenue		Change			2022		Revenue		2021		Revenue		Change
Treatment	$	6,273		81.4	$	6,145		78.4	$	128		$	6,841		91.5	$	6,570		87.7	$	271
Services		8,906		105.5		12,592		88.6		(3,686	)		7,438		88.2		14,207		90.8		(6,769	)
Total	$	15,179		94.0	$	18,737		85.0	$	(3,558	)	$	14,279		89.7	$	20,777		89.8	$	(6,498	)

	Three Months Ended June 30,							Six Months Ended June 30,
(In thousands)	2021		2020		Change			2021		2020		Change			2022		2021		Change
Administrative	$	10	$	37	$	(27	)	$	24	$	44	$	(20	)	$	17	$	14	$	3
Treatment		43		52		(9	)		90		145		(55	)		65		47		18
Services		19		46		(27	)		32		112		(80	)		14		13		1
PF Medical		72		74		(2	)		149		140		9			—		76		(76	)
Total	$	144	$	209	$	(65	)	$	295	$	441	$	(146	)	$	96	$	150	$	(54	)

(In thousands)
Cash provided by operating activities of continuing operations	$	803		$	148
Cash used in operating activities of discontinued operations		(315	)		(142	)
Cash used in investing activities of continuing operations		(649	)		(321	)
Cash used in financing activities of continuing operations		(439	)		(189	)
Effect of exchange rate changes in cash		9
Decrease in cash and finite risk sinking fund (restricted cash)	$	(591	)	$	(504	)

	●	~~revised~~waived our ~~fixed charge coverage ratio (“FCCR”) calculation~~failure to meet the minimum quarterly FCCR requirement ~~which allows~~ for the ~~add-back~~fourth quarter of ~~approximately $5,318,000 in eligible expenses that were incurred~~2021;
	●	removes the quarterly FCCR testing requirement for the first quarter of 2022;
	●	reinstates the quarterly FCCR testing requirement starting for the second quarter of 2022 and ~~covered by~~revises the ~~PPP Loan that we received in 2020. The add-back is~~methodology to be ~~applied retroactively~~used in calculating the FCCR for the quarters ending June 30, 2022, September 30, 2022, and December 31, 2022 (with no change to the ~~second~~minimum 1.15:1 ratio requirement for each quarter);
	●	requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and ~~third quarters of 2020. (see below for a discussion of~~certified to the ~~PPP Loan);~~lender; and
	●	arevises the annual rate used to calculate the Facility Fee (as defined in the Loan Agreement) on the revolving credit, with addition of the capital expenditure line, from 0.375% to 0.500%. Upon meeting the minimum FCCR requirement of ~~up to $1,000,000 with advances~~1.15:1 on ~~the line, subject to certain limitations, permitted for up to~~a twelve months ~~starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during~~trailing basis, the ~~Borrowing Period (see annual~~Facility Fee rate of ~~interest below on the capital expenditure line). At the end of the Borrowing Period, the total amount advanced under the line~~0.375% will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of June 30, 2021.be reinstated.

	●	~~waived our failure to meet the minimum quarterly FCCR requirement for the second quarter of 2021;~~
	●	~~removes the quarterly FCCR testing requirement for the third quarter of 2021;~~
	●	reinstates the quarterly FCCR testing requirement starting for the fourth quarter of 2021 and revises the methodology to be used in calculating the FCCR for the quarters ending December 31, 2021, March 31, 2022, and June 30, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter); ~~and~~
	●	requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended December 31, 2021 has been met and certified to the lender.

Item 3.	Quantitative and Qualitative Disclosures about Market Risks